

Author Index to Volumes 58-64

- A
Aatola M, 62:75
Abbs-Fehler M, 61:101
Abe T, 62:88; 62:140
Abe Y, 58:181
Acuto S, 58:71
Adamson DJA, 61:204
Agurell E, 61:53
Aitken M, 61:31
Akabane T, 59:9
Akatsuka J-I, 64:86
Alimena G, 60:93
Allen GA, 58:60
Aloe-Spiriti MA, 60:93
Alter BP, 58:206
Altmannberger M, 62:203
Aly MS, 63:43; 66:99
Amoss MS Jr, 61:77
Amylon M, 58:121
Andoh A, 62:88
Andreassen A, 64:178
Andrén-Sandberg A,
58:191; 62:43; 63:22
Antonucci A, 58:210;
59:45; 61:162
Applegate LA, 64:158
Archimbaud E, 58:177
Ardanaz MT, 62:108
Ardisia C, 60:195
Armstrong E, 62:75
Armstrong JA, 59:119
Arrigoni G, 59:51
Asari E, 61:152
Asou N, 61:197
Atkin NB, 58:198; 59:54;
62:106
Auerbach AD, 58:209
Augustus M, 59:93; 64:35
Austin MJF, 64:69
Aye MT, 59:99
- B
Badia L, 64:12
Bagg A, 62:134
Bailey CC, 60:135
Bak-Jensen E, 62:43
Baker MC, 59:54; 62:106
Balasubramanian S, 61:142
Bamba T, 62:88
Bamezai R, 61:142
Bankier Z, 61:1
Banting G, 60:20
Bapsy PP, 59:93
Barbasen H, 60:45
Barbata G, 58:18; 61:147
Barbieri-Neto J, 64:127
Bardi G, 58:191; 62:43;
63:22
Barin C, 60:206
Barisone E, 59:177
Barnard DL, 58:143
Baron HM, 62:15
Barranger JA, 59:12
Barreiro E, 61:174
Barrios L, 58:152;
59:217
Barroso MLB, 61:139
Bartelt DH Jr, 61:61
Bartnitzke S, 60:23; 62:29
Bassan R, 58:75
Basso G, 59:213; 62:124
Batcup G, 60:135
Bates P, 60:183
Batts KP, 61:61
Bauknecht T, 61:26
Beattie CW, 61:77
Beazley RM, 61:96
Becker RA, 62:53
Behm FG, 58:121
Belge G, 60:23
Bello MJ, 63:78
Bellomo MJ, 59:138
Bénard J, 60:14
Benítez J, 59:68; 60:108;
62:208
Bennett J, 60:82
Benoit Y, 60:216
Berger C, 60:27; 62:166
Berger CS, 58:52; 61:134;
62:130; 63:62
Berger R, 58:204; 61:201;
61:210; 63:97
Beris P, 59:138
Bernell P, 59:97
Besses C, 60:117; 60:131;
64:12
Bettelheim P, 61:14
Bhargava MK, 58:134;
60:86
Bhattacharya M, 59:180
Bianchi C, 58:210
Bianchi MS, 59:26; 64:133
Bianchi NO, 59:26; 64:133
Bielfeld V, 61:74
Bignon J, 59:1
Birdsall SH, 60:74
Bloxham D, 62:186
Blumstein L, 60:202
Bobrisheva IV, 62:15
Bolzán AD, 59:26; 64:133
Bongarzone I, 64:38
Bono AV, 64:30
Boogaerts M, 59:161
Boop FA, 60:152
Borgström GH, 72:75
Borowitz MJ, 58:121
Borresen A-L, 64:21
Børresen AL, 64:178
Bourrouillou G, 63:37;
64:49
Bown N, 60:190; 62:197
Brandi ML, 63:17
Bratescu L, 71:77
Breitbart EW, 58:186; 61:74
Brem H, 60:67
Bremond JL, 60:206
Briault S, 60:206
Bridge JA, 58:2; 60:27;
62:50; 64:95; 64:104
Brøgger A, 59:62; 64:21
Brøndum-Nielsen K, 59:97
Brosjö O, 60:170
Brothman AR, 62:180
Brown KW, 58:66
Browne CF, 60:135
Brugnatelli S, 61:218
Bui T-H, 59:219
Bullerdiek J, 60:23; 62:29
Burian P, 58:14
Butler MG, 58:60
Byrne JA, 59:206
- C
Caballín MR, 60:117;
60:131; 64:12
Cabello P, 58:96; 60:210
Caillot D, 60:90
Calabrese C, 63:52
Calabrese G, 58:210;
59:45; 61:162
Calasanz MJ, 62:108
Calvas P, 63:37
Campanari N, 60:195
Campos L, 58:177
Capra E, 59:51; 63:17
Caradonna F, 61:147
Carbone P, 58:18; 58:71;
61:147
Cariani TC, 64:38
Carlén B, 60:147
Carlson A, 59:73
Carneiro F, 61:39
Caronia F, 58:71
Carozzi F, 64:170
Carroll AJ, 58:121
Carson BS, 60:67
Casali M, 58:75; 61:152;
61:218
Casalone R, 64:30
Casciano I, 60:1
Cassileth P, 60:82
Cassileth PA, 59:89
Cassiman JJ, 59:161; 63:8
Castagnoli A, 61:11
Castedo S, 61:39; 63:102
Castoldi GL, 61:11
Castro PM, 59:68
Catovsky D, 58:29
Cavallaro AM, 61:147
Cedrone M, 60:93
Cepulic M, 60:158
Cerrillo M, 59:80
Cervantes G, 59:80
Chaddock WM, 60:152;
64:75
Chaganti RSK, 64:107
Chaganti SR, 62:9
Chakravarti A, 62:58
Challis J, 58:48
Chan AYY, 58:92; 62:47
Chan LC, 58:92; 59:95;
62:47; 62:154; 64:27;
64:93; 64:97; 64:192
Chan TK, 62:154
Chang J-J, 61:122
Charrin C, 58:177
Chattopadhyay S, 59:210
Chebotarev AN, 58:24
Cheerva AC, 64:60
Chen P-M, 61:122
Chen Y-C, 59:191
Chen Z, 58:212; 61:106;
62:130; 63:62
Cheng G, 59:99
Chin W-M, 59:191
Ching LM, 62:154; 64:27
Chiou TJ, 61:122
Christensen BE, 59:35
Chlecq C, 59:1
Chow CW, 58:55
Chowdhury V, 58:29
Christiansen H, 62:203
Christodoulidou F, 64:174
Chu YC, 58:92
Chuang S-M, 59:191
Chudoba I, 58:60
Cigudosa JC, 62:108
Cigudosa JCC, 64:99
Cin PD, 60:99; 63:43
Clark RE, 58:89
Clement D, 64:49
Clynes M, 59:111

- Coadic LP, 60:105
 Colelctor MJ, 64:145
 Coll MD, 60:117; 60:131;
 64:12
 Collins GG, 64:80
 Colombies P, 63:37; 64:49
 Colpaert C, 60:176
 Comelli A, 62:124
 Comoglio PM, 64:170
 Corcione A, 63:70
 Cornillet P, 60:14
 Corominas M, 59:217
 Correa de Moraes L, 64:127
 Correia C, 61:39
 Cortinovis M, 63:17
 Couillin P, 60:14
 Couturier J, 61:50
 Cowell JK, 64:1
 Craig J, 58:29
 Crotty TB, 61:61
 Cui MY, 59:12
 Culligan DJ, 62:66
 Cuneo A, 61:11
 Currie JL, 60:60
 Cuvelier C, 60:216
 Czarnecki D, 61:1
- D
 Dahlenfors R, 58:14
 D'Allesandro E, 58:100
 Dangou JM, 60:41
 Dastugue N, 63:37; 64:49
 Davare J, 61:131
 Davis JR, 58:52; 61:134
 Davis RI, 63:32
 Dawson VM, 59:119
 De Ambrosio A, 60:1
 De Braekeleer M, 59:135
 De Campos JM, 63:78
 De Cremoux H, 59:1
 de Graaf WE, 61:73
 de Gramont A, 61:216
 de Jong B, 61:73; 63:8;
 63:73
 de la Chapelle A, 64:21
 de la Chica R-A, 63:76
 De Long B, 60:216
 De Pasquale A, 58:100
 De Wever I, 63:43
 DeBoer JM, 64:95
 Decker H-JH, 63:25
 DeCoteau J, 64:166
 Deka R, 62:58
 Del Porto G, 58:100; 60:141
 Delasmorenas A, 64:65
 Della Porta G, 64:38
 Delle U, 62:111
 Dembinski A, 60:27
 Demidov LV, 58:24
 Deminatti M, 60:180
 Demur C, 63:37; 64:49
 Derré J, 61:201; 61:210;
 63:97
 Desalvo L, 58:29
 Devaux Y, 58:177
- Devi LV, 59:93
 Devine GC, 62:160
 Dewald GW, 61:61
 Dhaliwal MK, 64:158
 Di Cola M, 58:100
 Di Lorenzo R, 61:162
 Dijkhuizen T, 63:73
 Dinndorf P, 62:160
 Dipaolo JA, 60:214
 Diss L, 58:35
 Dobbs RM Jr, 63:100
 Dombret H, 58:204
 Dominis M, 60:158
 Donahue RP, 58:29
 Donaldson MH, 60:202;
 60:212
 Donti E, 60:195
 Donti VG, 60:195
 Dougherty CM, 62:166
 Drieschner O, 58:186
 Du Z-W, 58:160
 Dubé ID, 61:93; 64:166
 Duchayne E, 63:37
 Dutrillaux B, 59:1, 61:50
- E
 Echezarreta G, 59:68
 Economopoulos T, 58:201
 Edström S, 61:158
 Egozcue J, 58:152; 59:217;
 60:117; 60:131
 Ehlert U, 58:186; 61:74
 Elfving P, 64:99
 Ellwein LB, 64:42
 Eloo U, 61:74
 Endo Y, 59:9
 Escribano L, 58:96
 Evans J, 60:190
 Evers JP, 62:134
- F
 Faasse D, 60:202
 Facon T, 60:180
 Fan K, 62:150
 Fangen BM, 64:178
 Farag S, 58:48
 Farrington JE, 60:60
 Farrow GM, 61:61
 Favre B, 60:90
 Febre F, 60:105
 Fenaux P, 60:180
 Feng X-L, 58:79; 62:32;
 64:139
 Fernandez MH, 64:142
 Ferro MR, 60:210
 Ferro MT, 58:96
 Ferti A, 58:201; 58:214;
 59:220
 Fiere D, 58:177
 Finan JB, 59:89; 60:96
 Fioretos T, 59:35
 Fioritoni G, 59:45
 Fischer P, 62:186
 Fleischman EW, 64:183
- Fletcher CDM, 64:101
 Fletcher JA, 61:193
 Flexor M-A, 61:210; 63:97
 Florensa L, 64:12
 Flüry-Herard A, 59:1
 Fogu G, 61:152
 Foot ABM, 61:99
 Ford DS, 64:80
 Ford J, 59:119
 Fossá SD, 59:62, 64:21
 Fox MF, 58:198
 Fraccaro M, 59:51, 63:17
 Fraisse J, 58:177
 Franchi PG, 58:210; 59:45;
 61:162
 Frederiksen H, 62:43
 Freed M, 60:212
 Fresia AE, 60:60
 Frost G, 60:20
 Fugazza G, 62:124; 63:70
 Fujimoto M, 58:130
 Fujinaga K, 58:39
 Fujisawa K, 64:86
 Fujita C, 64:111
 Fujitake H, 58:130
 Fujiyama Y, 62:88
 Furuya T, 62:25
 Fuster C, 58:152
- G
 Gabbas A, 61:152
 Gadhia M, 64:158
 Gagniere M, 59:80
 Galinke I, 60:193
 Ganges MB, 60:111
 Gao XK, 62:191
 Garcia D, 63:76
 Garcia MTH, 61:139
 Garcia-Palazzo IE, 63:47
 García-Sagredo JM, 58:96;
 60:210
 Gardner A, 58:66
 Garson OM, 58:48; 58:55;
 59:128
 Gaschard P, 60:206
 Gebhart E, 61:6
 Gemmill RM, 60:125;
 62:166
 Geng J-S, 58:79
 Gerbault-Sereau M, 61:50
 Germain D, 58:177
 Giangaspero F, 59:213
 Giani S, 58:75
 Gibas Z, 58:169
 Giglio MC, 58:18
 Gilbert F, 59:210
 Gilchrist KW, 59:180
 Gilles FH, 59:12
 Gilsanz F, 61:174
 Gilvary V, 59:111
 Giordano S, 64:170
 Goepel JR, 61:31
 Gogineni SK, 62:98
 Golden WL, 60:102
 Gomes P, 61:39
- Gómez AO, 61:139; 64:142
 Gonzalez MLA, 60:45
 Gonzalez MT, 64:142
 Gonzalez R, 64:118
 Goovaerts G, 60:176
 Gorodezky G, 59:80
 Górski GK, 60:202; 60:212
 Goyns MH, 61:31
 Gramatzki M, 61:6
 Grammatico P, 60:141
 Granata G, 58:18; 61:147,
 61:147
 Granata P, 64:30
 Grant G, 59:111
 Green A, 61:77
 Gregory B, 59:111
 Grepp C, 58:14
 Griffin CA, 60:60; 60:67;
 61:183; 64:145
 Grison O, 60:105
 Grob JP, 59:138
 Gross AJ, 60:31
 Gulino SE, 64:149
 Gullon A, 62:108
 Gusterson BA, 60:74;
 64:101
 Guy H, 60:90
- H
 Haaf T, 61:104
 Haas O, 59:135
 Haas OA, 61:14
 Hägerstrand I, 59:191; 63:22
 Hautes NE, 61:204
 Hamamoto K, 58:130
 Hambraeus G, 60:219;
 63:95
 Hammond DW, 61:31
 Han Y-H, 64:69
 Hancock BW, 61:31
 Hanson CA, 59:89
 Hast R, 59:97
 Haupt R, 62:124; 63:70
 Hawkins AL, 64:145
 Hayashibara T, 58:105
 Heard S, 64:80
 Hecht B, 62:92
 Hecht F, 59:79; 60:89;
 60:188; 62:92
 Heerema NA, 64:60
 Heim S, 58:191; 59:35;
 60:147; 60:170; 60:198;
 60:219; 62:43; 63:22;
 63:95; 64:99; 64:163
 Heimdahl K, 59:62
 Heiurichs B, 58:96
 Henschke F, 61:6
 Heouaine A, 60:141
 Herens C, 60:45
 Hernandez TB, 64:142
 Herrera G, 63:25
 Herrmann ME, 62:144
 Herz J, 60:125
 Hidaka M, 61:197
 Higaki S, 60:35

- Higashi K, 64:163
Hillion J, 63:97
Himoe E, 62:134
Hirabayashi Y, 60:35
Hirata J, 58:181
Hodohara K, 62:88
Hoffner L, 62:58
Hogg A, 64:1
Hoggarth C, 62:186
Holmin T, 63:22
Honda T, 58:39
Hoo JJ, 64:186
Hopman A, 62:171
Hopwood VL, 60:164
Horiike S, 58:130
Horowitz SB, 59:20
Horsman D, 61:101
Horsthemke B, 63:1
Hoshi Y, 64:86
Hosick HL, 62:150
Hosoda S, 62:88
Hossfeld DK, 60:193
Hovig E, 64:178
Hu J, 62:200
Huang Q, 58:160
Huguet F, 63:37
Husain SA, 61:142
Hyde M, 61:101
- I
Ikeuchi T, 60:35
Inazawa J, 62:140
Inoue T, 62:88
Invernizzi R, 58:75; 61:152;
61:218
Isaacson PG, 58:35
Iselius L, 59:219
Ishida T, 60:35
Ishiguro M, 62:103; 64:111
Islam Q, 62:111
Ito H, 58:174
Iwabuchi A, 62:70
Iwasaki H, 62:103; 64:111
Iyori H, 64:86
- J
Jacobs A, 58:89; 59:167;
62:66
Jacobson RJ, 62:134
Jäger U, 61:14
Jankovic G, 62:100
Jankowski SA, 62:166
Jenkins RB, 61:61
Jin Y, 63:95
Johansson B, 58:191; 62:43;
63:22
Johansson L, 60:219; 63:95
Johansson M, 60:219; 63:95
Jones B, 64:186
Jones BM, 62:66
Jones RJ, 64:145
Juan JLC, 61:139; 64:142
- K
Kahls P, 61:14
Kamada N, 61:42
Kamihira S, 59:86
Kaneko Y, 62:103; 64:111
Kant JA, 59:89
Kao C, 59:180
Karakousis CP, 59:30
Karnes PS, 59:12
Kashima K, 62:140
Kato H, 58:39
Kawachi T, 58:105; 59:86
Kawai H, 59:9
Kawakubo K, 58:165
Kawano F, 61:197
Kees UR, 59:119; 59:128,
59:128
Kemshead JT, 60:20
Kernahan J, 60:190
Kessous A, 64:49
Kiechle-Schwarz M, 61:26
Kikuchi M, 62:103; 64:111
Kimber RI, 64:80
Kimura T, 58:130
Kindblom L-G, 62:111
King DJ, 61:204
Kintzel D, 58:109
Kirichenko OP, 58:24
Kishimoto Y, 58:130
Kitajima H, 58:130
Kitchen C, 61:99
Kitoh K, 62:88
Klauck SM, 63:25
Knisch VI, 64:183
Knuutila S, 60:8; 62:21;
62:171
Kodama A, 58:174; 62:70
Kojima T, 60:35
Köller U, 61:14
Koller-Weber E, 61:14
Komiya A, 59:9
Kommoss F, 61:26
Konja J, 58:155
Konstantinova LN, 64:183
Koops HS, 61:73
Köpf I, 62:111
Kopnin BP, 58:24
Kraemer PM, 59:39
Kreiner G, 61:14
Krous HF, 58:141
Krulik M, 61:216
Kupsky WJ, 61:193
Kusak ME, 63:79
Kwong YK, 62:154
Kwong YL, 58:92; 59:95;
62:47; 64:93
- L
Laasonen A, 60:8; 62:171
Labrañ X, 63:76
Lai JL, 60:180
Lakhani A, 61:93
Lalitha N, 64:35
Lalley PA, 62:144
Lampert F, 62:203
- Land VJ, 58:121
Larano JG, 60:210
Larramendy ML, 64:133
Latte G, 61:152
Laureys G, 60:216
Lavin MF, 60:183
Law E, 59:111
Lawrence KM, 61:61
Laxman R, 60:60
Le Beau MM, 60:82
Le Coniat M, 61:201;
61:210; 63:97
Le Poidevin P, 60:183
Leahy S, 61:1
Lecca U, 62:40
Lechner K, 61:14
Lee CP, 62:47
Lee FY, 59:191
Leifsson B, 60:198
Lejars O, 60:206
Leong SPL, 58:52; 61:134
Leroy JG, 60:176
Lewis IJ, 60:135
Lewiss JP, 61:46
Ley RD, 64:158
Li AP, 58:79
Li FP, 59:57
Li L, 62:191
Li P, 62:32; 64:139
Li R, 61:53
Li SJ, 62:191
Li X-N, 58:160
Li YS, 59:99
Liang R, 64:27
Liao M, 62:166
Lie KW, 59:95; 62:47; 64:97
Lier ME, 59:62
Ligas C, 58:100
Ligutić I, 60:158
Limon J, 58:196; 60:41
Lin D-T, 59:191
Lin K-H, 59:191
Linassier C, 60:206
Link MP, 58:121
List AF, 58:125
Little MH, 59:206
Liu C-J, 61:122
Liu HW, 62:47; 62:154;
64:27; 64:97
Liu J-H, 61:122
Liu M-C, 59:191
Liu Q-Z, 59:79; 62:32; 64:139
Liu X-Q, 58:79
Liu ZM, 63:47
Lo Re ML, 58:100
LoBue J, 62:9
Locatelli F, 58:75
Löffler-Badžak D, 60:158
Lombard M, 61:50
London B, 64:166
Long PP, 60:67
Longee DC, 64:75
Longy M, 60:105
Looijenga L, 63:8
Losanova T, 58:109
Lothe RA, 59:62; 64:21
- Louvet C, 61:216
Lovell MA, 60:102
Lowe LR, 64:60
Luke B, 59:99
Lukeis RE, 58:55
Lukovic L, 59:84; 61:26
Lundgren R, 64:99
Lutz D, 61:14
Lyberatos C, 58:201
Lynch V, 59:111
- M
Maccari A, 60:195
Macera MJ, 64:174
Machinami R, 60:35
MacLennan KA, 60:74
Madon E, 59:177
Maeda H, 59:86
Maekawa K, 64:86
Maggio A, 58:71
Maitland NJ, 58:66
Malliaros S, 58:214; 59:220
Mancini M, 60:93
Mandahl N, 58:191; 60:147;
10:170; 10:198; 60:219;
62:43; 63:22; 63:95;
64:99
Mannens MMAM, 61:111
Manolova Y, 61:214
Manso AIG, 61:174
Mansoor AM, 61:42
Maraschio P, 59:51; 63:17
Marceno R, 61:147
Marcillo AG, 61:174
Marcus R, 62:186
Marinduque B, 59:210
Marino M, 59:45
Mark J, 58:14; 58:85; 61:158
Marks JL, 61:96
Marosi C, 61:14
Marsden KA, 64:80
Martin H, 58:109
Martinez-Castro P, 62:208
Martinsson T, 62:111
Mascarello JT, 58:141
Maserati E, 58:75; 61:152;
61:218
Mason MK, 58:143
Matsuki C, 64:163
Matsuo T, 58:105
Matsuzaki H, 61:197
Mattson K, 60:8; 62:21;
62:171
McDermott A, 58:66
McMorrow LE, 60:202;
60:212
McRobert TL, 58:55;
59:128
Mecucci C, 59:161; 60:93
Medina JW, 58:29
Meehan C, 61:1
Meese EU, 59:20
Meeus P, 59:161
Meloni AM, 59:57; 61:108;
61:131; 63:100

- Meltzer PS, 62:166
 Mendez MJ, 62:166
 Meroni E, 64:30
 Meuzelaar JJ, 63:73
 Micale MA, 61:165
 Miettinen M, 58:169
 Milasin J, 59:84
 Milunsky A, 59:73; 61:96;
 64:65
 Milunsky JM, 61:96
 Min T, 58:29
 Minelli E, 64:30
 Miniero R, 59:177
 Miozzo M, 64:38
 Miranda JLG, 61:139;
 64:142
 Miró R, 58:152, 59:217
 Mirto S, 58:18; 58:71
 Misawa S, 62:140
 Mitchell D, 62:166
 Mitelman F, 58:191; 60:147;
 60:170; 60:198; 60:219;
 62:43; 63:22; 63:95;
 64:99
 Mitra J, 62:9
 Miyamoto S, 58:39
 Miyamishi S, 59:199
 Modesti A, 60:141
 Moerman P, 63:43
 Moertel CA, 61:61
 Moesker O, 62:171
 Mohamed A, 61:165
 Mohar A, 59:80
 Molenaar WM, 63:73
 Möller P, 59:62
 Montaldo A, 59:213
 Montero S, 60:131
 Moore GE, 63:32, 64:118
 Moraine C, 60:206
 Morgan GJ, 58:29
 Morgan R, 58:125; 58:212;
 61:106; 62:25; 62:130;
 63:62
 Mori PG, 63:70
 Morse HG, 64:118
 Morton CC, 61:193
 Mott MG, 58:66
 Motzer RJ, 64:107
 Motzko H, 62:29
 Mouron BJ, 58:2
 Mrózek K, 58:196
 Mugneret F, 60:90
 Mühlematter D, 59:138
 Mukerio AF, 58:24
 Muleris M, 61:50
 Müllerleile U, 60:193
 Murakami T, 58:174, 62:70
 Murphy BA, 62:160
 Musio A, 62:81
- N
 Nacheva E, 62:186
 Nadal N, 62:206
 Nagai K, 58:105
 Nagano T, 58:130
- Najfeld V, 63:89; 64:56
 Nakagawa H, 62:140
 Nakahata T, 59:9
 Nakamura H, 58:105; 59:86
 Nakić M, 58:155; 60:158
 Narváez L, 59:173
 Narváez R, 59:173
 Nash CG, 61:1
 Nawata H, 58:181
 Nedoszytko B, 58:196; 60:41
 Neff JR, 58:2; 60:27; 62:50;
 64:95
 Negri D, 62:124; 63:56
 Negrini M, 61:11
 Neyra O, 59:80
 Nieto LH, 61:139
 Ning Y, 60:31
 Nisch G, 58:109
 Nishida J, 58:39
 Nishimura J, 58:181
 Nisson PE, 63:81
 Niwakawa M, 62:88
 Noel JC, 60:41
 Nordkvist A, 61:158
 Norming U, 61:53
 Novak A, 62:100
 Nowell PC, 59:89; 60:96
 Nowotny H, 61:14
- O
 Oakhill A, 61:99
 Oberling F, 62:206
 O'Brien T, 61:1
 Ocampo L, 59:173
 O'Connor S, 62:186
 Ogata T, 62:1
 Oguma N, 61:42
 Ohaga S, 58:130
 Ohgami A, 62:103; 64:111
 Ohjimi Y, 62:103; 64:111
 Ohno H, 59:199
 Ohto T, 58:165
 Ohyashiki JH, 58:165;
 58:174; 62:70
 Ohyashiki K, 58:165;
 58:174; 62:70
 Okamoto T, 64:163
 Olegård C, 60:198
 Oosterhuis JW, 61:73; 63:8
 Örndal C, 60:147; 60:170
 Osella P, 59:73; 64:65
 Osornio A, 59:80
 Ostijn F, 60:99
 Otero Gomez AO, 61:139
 Ozisik YY, 61:131
- P
 Pai GS, 60:31
 Paietta E, 60:82
 Palazzo JP, 63:47
 Palka G, 58:210; 59:45;
 61:162; 63:52
- Palmer CG, 64:60
 Pan L, 58:35
 Panani A, 58:201
 Panani AD, 58:214; 59:220
 Pandis N, 58:191; 62:43;
 63:22
 Parada L, 58:96
 Parlier V, 59:138
 Pasquali F, 58:75; 61:152,
 61:152
 Patel AM, 62:180
 Patel K, 60:20
 Pathak S, 60:164; 60:158
 Paulien S, 60:125; 62:166
 Payen C, 64:49
 Paz-y-Miño C, 59:173
 Pazzi I, 61:11
 Pearse AM, 64:80
 Pedersen B, 60:53
 Pedersen NT, 59:35
 Peehl DM, 62:180
 Pellicer A, 59:217
 Peltomäki P, 64:21
 Perdahl-Wallace E, 63:89
 Perevozchikov AG, 64:183
 Pestana A, 63:78
 Petit A, 60:206
 Petković I, 58:155; 60:158
 Pfeleiderer A, 61:26
 Picardo M, 60:141
 Pierotti MA, 64:38
 Pilotti S, 64:38
 Pinkerton PH, 61:93;
 64:166
 Piras A, 62:81
 Pirc-Danoewinata H, 61:14
 Pittaluga S, 64:192
 Plaisancie H, 63:37; 64:49
 Plaja A, 63:76
 Polliack A, 58:29
 Pontes JE, 63:100
 Ponzetto C, 64:170
 Popescu NC, 60:214
 Portentoso P, 64:30
 Potter AM, 61:31
 Povirk LF, 64:69
 Powell IJ, 61:165
 Pozzi E, 64:30
 Pratt CI, 59:180
 Prete L, 58:75
 Preudhomme C, 60:180
 Prieto E, 60:108
 Prieto F, 64:12
 Pris J, 63:37
 Pueyo JM, 63:76
 Pullen J, 58:121
 Purtilo DT, 64:42
 Putti MC, 59:213
 Pyrhönen S, 60:8; 62:21;
 62:171
- Q
 Quaglini D, 58:100
 Querzola F, 60:1
- R
 Raffel C, 59:12
 Rainaldi G, 62:81
 Rainho CA, 64:127
 Ramaekers F, 62:171
 Ramel C, 61:53
 Ramesh KH, 60:86
 Ramirez WR, 62:98
 Ranford PR, 59:119
 Rannug U, 61:53
 Rao PH, 61:207
 Rao UNM, 59:30; 60:78
 Raptis S, 58:214; 59:220
 Rautonen J, 60:8; 62:21
 Ravisse N, 60:14
 Ray FA, 59:39
 Reece D, 61:101
 Reeves BR, 64:101
 Rege-Cambrin G, 64:170
 Reid MM, 60:190
 Reis MD, 61:93; 64:166
 Resino M, 58:96; 60:210
 Reuter V, 61:207
 Reuter VE, 64:107
 Rey JA, 63:78
 Reynoso E, 59:80
 Reznikoff CA, 59:180
 Richard F, 61:50
 Richkind KE, 61:126
 Righi R, 64:30
 Rigobello L, 59:213
 Risin S, 60:164
 Ritouet D, 58:177
 Rivas C, 59:68; 62:208
 Robbins JH, 60:111
 Robert A, 64:49
 Robert P, 60:135
 Robinson WA, 64:118
 Robledo M, 59:68, 62:208
 Rodriguez E, 61:207; 64:107
 Rogatto SR, 64:127
 Roloson GJ, 60:152; 64:75
 Rolovic Z, 62:100
 Romani M, 60:1
 Roncella S, 62:124
 Rondinelli MB, 60:93
 Rosenhagen C, 62:29
 Rosenthal CJ, 62:98
 Rossi C, 58:210
 Roth D, 62:130
 Royle G, 64:91
 Rubbert A, 61:6
 Rubie H, 64:49
 Rudduck C, 58:55; 59:128
 Rüdiger HW, 58:186; 61:74
 Rümmelein B, 58:186;
 61:74
 Rydholm A, 60:170
- S
 Sacchi N, 63:81
 Sadamori N, 58:105; 59:86;
 59:86
 Saglio G, 64:170
 Sahlin P, 58:85
 Sainati L, 59:213

- Sakai N, 58:174
 Sakr W, 61:165
 Salles M-T, 59:80
 Salvatore M, 64:30
 San Román C, 58:96;
 60:210
 Sanada I, 61:197
 Sandberg AA, 58:1; 58:52;
 58:125; 58:169; 58:212;
 59:30; 59:57; 60:27;
 60:78; 60:125; 61:106;
 61:108; 61:131; 61:134;
 62:25; 62:130; 62:166;
 63:25; 63:32; 63:62;
 63:100
 Sanna R, 61:152
 Sans-Sabrafen J, 60:117;
 64:12
 Sansone R, 62:124; 63:56;
 63:70
 Santon A, 59:68
 Santoro A, 58:18; 58:71
 Santos G, 61:183
 Santos J, 62:94
 Santos M, 59:68
 Sarasa JL, 63:78
 Sarashina N, 64:163
 Sasao I, 62:70
 Saura R, 60:105
 Sawyer JR, 60:152; 64:75
 Scalise A, 63:89; 64:56
 Scappaticci S, 63:17
 Scaravaglio P, 64:170
 Scarpa S, 60:141
 Scheerer PP, 58:212
 Schellhammer PF, 62:180
 Schmid M, 61:104
 Schmidt J, 61:26
 Schneider B, 61:14
 Schwartz HS, 58:60
 Schwarzingler I, 61:14
 Sciappaticci S, 59:51
 Secker-Walker LM, 58:29
 Segers A, 60:99
 Seguin LR, 60:111
 Seibel N, 62:160
 Seizinger BR, 63:25
 Senn JS, 61:93
 Seruca R, 61:39
 Sessarego M, 62:124;
 63:70
 Shah NK, 61:183
 Shailaja SN, 64:35
 Shamdas GJ, 58:125
 Sharkis SJ, 64:145
 Sheahan K, 61:96
 Sheer D, 63:52
 Shen M-C, 59:191
 Shen-Schwarz S, 62:58
 Shend WPV, 64:189
 Sher GD, 61:93
 Shi Y-H, 62:32; 64:139
 Shigeta C, 61:42
 Shilkaitis A, 61:77
 Shinohara N, 64:111
 Shirashi Y, 62:1
 Sidaner I, 60:90
 Silengo M, 59:177
 Silver RT, 64:174
 Silverman L, 63:89; 64:56
 Simi P, 61:152; 64:30; 64:30
 Simi S, 62:81
 Simon P, 60:41
 Sinovic JF, 62:50
 Slater RM, 61:111
 Sleijfer DT, 61:73
 Smadja N, 61:216
 Smith PJ, 59:206
 Smith SR, 62:197
 Sneyers W, 60:99
 Soares P, 61:39
 Sobrevilla-Calvo P, 59:80
 Sobrinho-Simões M, 61:39
 Sokova OI, 58:24
 Solary E, 60:90
 Solé F, 60:117; 60:131;
 63:76; 64:12
 Soma H, 62:1
 Sørensen A-G, 59:35
 Sozzi G, 64:38
 Spadano A, 59:45; 61:162
 Speleman F, 60:176; 60:216;
 62:40
 Spicer RD, 60:135
 Spier C, 58:125
 Sreekantaiah C, 59:30;
 59:135; 60:78; 64:107
 Srigley JR, 64:166
 Stanley WS, 62:160
 Steegman JL, 58:96
 Steger G, 61:14
 Steindl K, 60:141
 Stella M, 59:213
 Stenman G, 58:85; 61:158
 Stephenson CF, 58:52;
 59:57; 61:134; 63:32
 Stierner U, 62:111
 Stone JF, 62:130
 Streekantaiah C, 58:134
 Strigini P, 63:70
 Stul M, 59:161
 Stuppia L, 58:210; 59:45;
 61:162
 Sudduth KW, 60:102
 Suijkerbuijk R, 60:216
 Suijkerbuijk RF, 63:8
 Sundareshan TS, 59:93;
 64:35
 Surti U, 61:131; 62:53;
 62:58; 62:200
 Suzushima H, 61:197
 Swansbury GJ, 58:29
 Swanson CM, 64:75
 Szego K, 64:186
 T
 Tabilio A, 60:195
 Taguchi F, 58:181
 Taguchi T, 63:47
 Taine L, 60:105
 Taja L, 59:80
 Takashima T, 62:140
 Takatsuki H, 58:181
 Takatsuki K, 61:197
 Tallarico A, 61:11
 Tammilehto L, 60:8; 62:21;
 62:171
 Tanaka K, 61:42; 61:197
 Tanaka S, 62:140
 Taniguchi H, 58:130
 Taniwaki M, 62:140
 Tarone RE, 60:111
 Tauchi T, 58:165
 Taylor N, 61:46
 Teerenhovi L, 62:75
 Testa JR, 63:47
 Teyssier J-R, 60:14
 Theodossiou C, 63:89; 64:56
 Thiel G, 58:109
 Thode B, 60:23
 Thomas EL, 60:152
 Tiainen M, 60:8; 62:21;
 62:171
 Tien H-F, 59:191
 Tobon JP, 62:200
 Todd D, 62:152
 Tomonaga M, 58:105; 59:86
 Tonk V, 64:65
 Tonomura A, 60:35
 Torlontano G, 59:45; 61:162
 Towne B, 64:189
 Toyama K, 58:165; 58:174;
 62:70
 Tran TN, 59:12
 Trautmann U, 61:6
 Travis JA, 64:104
 Trent JM, 59:20; 62:166
 Tribukait B, 61:53
 Troy K, 63:89
 Tse E, 64:192
 Tsikritzi H, 58:201
 Tsuji Y, 59:86
 Tumewu P, 64:91
 Tzeng C-H, 61:122
 U
 Uettwiller F, 62:206
 Ulrich E, 60:14
 Urashima M, 64:86
 Urumov IJ, 61:214
 V
 Valiente A, 60:108
 Valtat C, 60:206; 62:206
 Van Damme B, 60:99
 van den Berg E, 63:73
 Van Den Bergh H, 59:161;
 60:99; 63:43
 van Echten-Arends J, 61:73
 van Kessel AG, 63:8
 Van Marck E, 60:176
 Van Ness B, 60:82
 Van Roy N, 62:40
 Vanni R, 62:40
 Vaquero J, 63:78
 Varette C, 61:216
 Varshaver NB, 62:15
 Vassallo E, 59:177
 Vatteroni L, 62:81
 Veomett I, 58:125
 Verhest A, 60:41
 Verhoef G, 59:161
 Verma RS, 62:98; 74:174
 Vidal G, 60:1
 Viégas-Pequignot E, 59:1
 Vorpahl K, 58:109
 W
 Wagner B, 61:14
 Wagner J, 61:183
 Wakabayashi Y, 59:9
 Wake N, 58:39
 Wallis JP, 62:197
 Walter TA, 60:193
 Walz L, 61:26
 Wan SK, 64:27
 Wang C-H, 59:191
 Wang HS, 59:99
 Wang L, 62:191
 Wason D, 61:126
 Watkins PC, 63:81
 Watson MS, 58:121
 Wedell B, 58:14
 Weh H-J, 60:193
 Wei W, 62:32
 Weichenthal M, 58:186;
 61:74
 Weiss A, 60:96
 Welborn JL, 61:46
 Wenger SL, 61:213; 62:53
 Wennerberg S, 60:147
 Weremowicz S, 61:193
 Wessman M, 62:171
 Westbrook CA, 63:52
 Whaley JM, 63:25
 White AD, 58:89; 59:167;
 62:66
 White J, 58:48
 White RD, 61:108
 Wiernik PH, 60:82
 Wiersema-Buist J, 61:73
 Willén H, 60:147; 60:170;
 60:198
 Williams J, 58:143; 60:135
 Williams JC, 58:66
 Williams SV, 58:143
 Witkowski R, 58:109
 Woessner S, 60:117; 60:131;
 63:76; 64:12
 Wolman SR, 61:165
 Wong KF, 58:92
 Wotherspoon AC, 58:35
 Wu S-Q, 59:180
 Wullich B, 63:25
 Wyandt H, 59:73
 Wyandt HE, 61:96; 64:65
 X
 Xiao S, 58:79; 62:32; 64:139

Y

Yamada T, 58:29
Yandell DW, 63:25
Yasha TC, 59:93; 64:35;
64:35
Yasunaga K, 58:130
Yialamboukides M, 58:201

Ying KL, 59:12
Yongshan Y, 60:31
Yoshida MA, 60:35
Yoshioka A, 58:130
Yoshitake K, 64:111
Yule SM, 60:190
Yunis JJ, 62:94

Z

Zadeh TM, 64:189
Zalcberg J, 61:1
Zandecki M, 60:180
Zanesco L, 59:213
Zecca M, 58:75
Zehmbauer BA, 64:145

Zhengang L, 62:150
Zhou HY, 62:191
Zicha MS, 64:145
Zwiebel JA, 62:134

Subject Index to Volumes 58-64

- Acute Biphenotypic Leukemia**
 chromosome changes in, 64:56
 evolution in MDS with +21, 64:56
- Acute Erythroleukemia (M6)**
 chromosome changes in M6, 59:45; 60:117; 61:24
 prognosis, karyotype and immunology, 61:14
 t(6;9)(p21;q34) in, 59:48
- Acute Lymphoblastic Leukemia (ALL)**
 application of FISH, 63:62
 biphenotypic and early progenitor phenotype and 5q-, 63:89
 biphenotypic evolution, 62:124
 childhood ALL, 64:49
 chromosome changes in, 58:121; 59:191; 60:206; 61:126, 201, 218; 62:124, 154, 197; 64:49, 60
 chromosome 5 in, 61:106
 chromosome 13, 60:206
 congenital, 62:124; 63:56
 correlation with immunophenotype and genotype, 59:191
 deletions in, 59:191
 duplication of der(14) in L3 ALL, 61:218
 i(13q) in adult ALL, 60:193
 immunophenotype and genotype in, 59:191
 in Hong Kong, 62:154
 L3 with t(14;18) and atypical (8;22), 62:197
 L3 (Burkitt type), 60:206; 61:228; 62:197
 molecular studies in, 59:191
 molecular studies in case with t(2;9) and t(4;11), 60:82
 neonatal, 62:124
 prognosis and karyotype, 64:49
 survival and karyotype in children, 64:49
 T-ALL with t(8;14)(q24;q13), 64:86
 T-cell ALL cell line, 64:86
 telomere shortening, 61:204
 translocations in, 59:191; 62:124
 t(2;9) in a case with t(4;11), 60:82
 t(2;14)(p13;q32) in, 58:121
 t(2;14;12)(p13;q32;q11), 58:121
 t(2;16)(p11.2;p11.2) in ALL, 64:60
 t(2;17) in ALL (L1), 64:27 (Table)
 t(8;14) in L3 ALL, 61:218
 +4 in, 62:88
 5q- in ALL, 61:201; 63:89 (Table)
 20q- in, 62:75
 -20 in, 59:177
- Acute Megakaryocytic Leukemia (M7)**
 chromosome changes in, 58:155; 60:117; 61:25
 neonatal (congenital), 63:56
 prognosis, karyotype and immunology, 61:14
- Acute Monoblastic Leukemia (M5)**
 chromosome changes in, 58:71, 155; 59:45; 60:117; 61:25, 99
 ETS2 amplification, 58:71
 in Klinefelter syndrome, 61:99
 neonatal (congenital), 63:56
 prognosis, karyotype and immunology, 61:14
 t(4;14)(q31;q32) in, 59:46
 t(6;21;18) in, 58:71
 t(8;22)(p11;q13), 60:180
 t(9;11) in, 58:155
 8p11 in, 60:180
- Acute Monocytic Leukemia (AML) (M1); see Acute Monoblastic Leukemia**
 chromosome changes, 58:155; 59:45, 138; 60:117; 61:24, 139 62:154
 in RAEB-t, 59:138
 inv(3)(q21;q26), 59:138
 prognosis, karyotype and immunology, 61:14
 thrombopoiesis and inv(3), 59:138
 t(1;7)(p11;p11) and survival, 60:53
 t(4;14)(q11;q32) and other translocations in, 59:45
 t(6;9)(p22;q34) in, 63:76
 t(8;21) in, 58:155
 t(15;21) and 5q- in, 61:139
 +4 in, 60:195
 +8 in, 62:70
- Acute Myeloblastic Leukemia (M2)**
 chloroma and t(8;15;21), 64:35
 chromosome changes in, 58:155; 59:48, 86; 60:117; 61:24, 139 62:154; 64:93
 chromosome 18 in, 63:97
 del(16)(q22) in child with, 59:86
 inv(3)(q21;q26) with normal thrombopoiesis, 59:93
 lack of eosinophilia in M2 with del(16), 59:86
 molecular studies of t(8;21), 63:81
 prognosis, karyotype and immunology, 61:14
 translocations in, 59:48
 t(1;7)(p11;p11) and survival, 60:53
 t(2;4)(p23;q35) in M2, 58:48
 t(8;15;21) in M2, 64:35
 t(8;21) in, 58:155
 t(15;21) and 5q- in, 61:139
 Y changes, 61:101
 2p23 in M2, 58:48
 +4 in, 60:195
 6q- in M2, 58:181
 +21 and 9q- in, 64:93
 -21 in, 61:122
- Acute Myeloid Leukemia; see also Acute Nonlymphocytic Leukemia**
 application of FISH, 63:63

- SCE and cell cycle in marrow, 62:66
 t(8;15;21) in, 64:35
 12p- in, 62:47
- Acute Myelomonocytic Leukemia (AMMoL) (M4)**
 abnormal X, 62:130
 chromosome changes in, 58:29, 130, 155, 204; 59:35, 48, 138; 60:117; 61:24, 126; 62:130, 154
 del(16) in, 59:87
 eosinophilia in, 58:29, 204
 FISH studies of abnormal X, 62:130
 in children, 58:155
 in MMM, 59:138
 inv(3)(q21q26), 59:138
 inv(16) in, 58:29, 130; 59:35
 inv(16) M4 complicating Ph+ CML, 59:35
 neonatal (congenital), 63:56
 Ph chromosome in, 58:29; 59:35
 prognosis, karyotype and immunology, 61:14
 thrombopoiesis and inv(3), 59:138
 transformation with inv(16) and eosinophilia in Ph+ CML, 61:197
 translocations in, 59:48, 87
 t(1;7)(p11;p11) and survival, 60:53
 variant translocation of 16, 58:204
 +4 in, 60:195
 5q- and 16q22 mosaicism, 58:130
- Acute Nonlymphocytic Leukemia (ANLL)**
 AA, AN and NN system, 59:45, 62:154
 abnormal X in M4, 62:130
 antigen (red cell A and Le^b) loss, 64:80
 biconality, 62:25
 cytogenetic changes, 58:18, 29, 48, 130, 155, 177, 181, 204; 59:45, 86; 60:117; 61:24, 126, 139; 62:26, 154
 deletions in ANLL, 62:27
 evolution and loss of antigens, 64:80
 in children, 58:155
 karyotype and immunologic phenotype, 61:14
 monosomy (5,7,21) in secondary, 58:18
 neonatal (congenital), 63:56
 prognosis and karyotype, 61:14
 secondary, 58:18
 survival in, 59:45
 telomere shortening, 61:204
 trisomy in ANLL, 62:27
 trisomy (8;11;15) in secondary 58:18
 t(1;3)(p36;q21) in, 64:80
 t(1;7)(p11;p11) and survival, 60:153
 t(2;4) in M2, 58:18; 59:48
 t(8;21)(q22;q22) in children with, 58:155
 t(15;17) and t(8;21) in APL (M3) 58:177
 t(15;21) and 5q- in, 61:139
 unbalanced 6p translocation, 60:93
 +4 in ANLL, 60:195
 +5 in Ph+ ANLL, 61:216
 6p in, 60:93
 6q- in M2, 58:181
 12p- in, 62:47
 20q- in, 62:75
 -21 in ANLL, 61:122
- Acute Promyelocytic Leukemia (APL) (M3)**
 chromosome changes in, 58:155, 177; 59:45; 60:117 61:24; 62:154
 prognosis, karyotype and immunology, 61:14
 t(15;17) and t(8;21) in, 58:177
 +8 in, 58:155
 +13 in APL, 62:206
- Adenomas**
 chromosome changes, 58:85; 60:23, 99; 63:32
 chromosome 7 in colonic, 63:122
 follicular, thyroid, 60:99
 INT1 and GLI in, 58:85
 of breast, 63:32
 pleomorphic and 12q13-15, 58:85
 salivary gland, 58:85
 thyroid, 60:23, 99; 64:35
- Adrenal Tumors**
 cortical carcinoma, 61:96
 cytogenetic studies of cancer, 61:96
- Angiosarcoma**
 childhood, 63:171
 chromosome changes, 63:171
- Aplastic Anemia**
 20q- in, 62:75
- Askin Tumor**
 chromosome changes in, 62:203
 t(5;22) in, 62:203
- Astrocytomas; see also Brain Tumors and Gliomas**
 anaplastic, 59:12
 cytogenetic changes, 58:111; 59:12, 106; 60:72, 152
 diffuse, 59:12
 dms in, 58:111
 low-grade, 60:72
 pediatric, 59:12
 pilocytic, 58:116; 59:12
 pleomorphic xanthoastrocytoma with ring, 60:152
 ring in, 60:152
 translocations in, 59:14
- Ataxia Telangiectasia (AT)**
 chromosome changes in, 60:158
 clinical findings, 60:158
 cytogenetic findings in AT with malignant diseases, 60:158
 heterozygotes, 60:183
 lymphoma in, 60:158
 radiation-induced G2 delay, 60:183
 translocations in, 60:158
- Banding**
 high resolution, 59:62
 in search for mutations, 59:62
- Bartholin gland**
 adenoid cystic carcinoma, 61:26; 63:153
 carcinoma, 61:26; 63:153
 cytogenetics of carcinoma, 61:26; 63:153
- Basal cell carcinoma**
 cytogenetics of, 63:183
- Basal cell epithelioma**
 fibroblast cultures, 67:74
 UV effects on fibroblasts, 67:74
- B-cell**

- ALL, 58:121
CLL, 60:131
DNaseI-sensitive sites, 62:94
lymphomas in United Kingdom, 61:31
molecular studies in lymphoma, 64:166
t(1;14)(q21;q32) in clonal expansion, 64:166
bcr (breakage cluster region)
 molecular studies, 61:11
 Ph+, bcr- CML, 61:11
Beckwith-Wiedemann syndrome
 duplication of HRAS and CALCA, 58:66
 imprinting at 11p15.5, 63:163
 imprinting in, 63:161; 63:163
 paternal origin of dup(11p15), 58:66
 11p15 duplication, 58:66
Bladder cancer
 cell line, 63:145
 chromosome findings, 59:105
 DNA fingerprint analysis, 61:53
 FISH in, 59:102
 heterogeneity of, 63:144
 karyotype and prognosis, 59:105
 interphase cytogenetics, 63:144-145
 multiple molecular genetic changes, 63:140
 progression, 63:145
Blastic phase of CML
 after BMT, 61:152
 bizarre blasts in, 58:92
 i(17q) detection by FISH, 62:140
 inv(16) and eosinophilia, 62:134
 karyotypic progression after 30 years, 60:96
 lymphoblastic crisis, 58:165
 myelomonocytic with inv(16) and eosinophilia, 62:134
 near-triploid, 58:92
 remission, 58:165
 t(6;8) in Ph+ CML, 61:104
 t(8;21)(q22;q22) in Ph+ CML, 58:96
 t(9;11)(p22;q23) in, 63:37
Bloom syndrome (BS)
 lymphoblastoid all lines, 62:1
 stomach cancer antigen derived from BS cells, 62:1
Bone
 chordoma, 58:169
 chromosome instability in tumors, 59:105
 cytogenetics of tumors, 63:125
 giant cell tumor, 58:2, 60
 osteogenic sarcoma, 58:60
 osteosarcoma, 58:60; 62:50
Bone marrow
 analysis, 61:46
 PMCL and myeloid metaphase, 61:46
Bone marrow transplantation (BMT)
 allogeneic in CML (Ph+), 61:152
 blast phase after BMT, 61:152
 chromosome changes after, 61:152
 graft-versus-leukemia, 61:152, 183
 in CML, 58:143; 61:152, 183
 karyotype at relapse of CML after BMT, 61:183
 Ph- cells after BMT, 58:143
 relapse of CML after allogeneic BMT, 61:183
Brain tumors
 childhood, 59:12, 104; 64:75
 chromosome changes in, 63:178
 chromosome method of analysis, 58:160
 direct preparation for cytogenetics, 58:160
 dms in, 58:109, 64:75
 gliomas, 58:109; 64:75
 karyotypes, 58:109; 59:12, 106; 64:75
 molecular and cytogenetic studies, 59:106
 molecular genetic analysis, 63:172
 mutation of p53 in siblings with brain tumor and rhabdomyosarcoma, 63:114
 pediatric, 59:12, 104; 64:75
 pleomorphic xanthoastrocytoma with ring, 60:152
 +7, -22,-Y,-X in, 58:109
 -10 in malignant glioma, 58:109
Breast
 allelic imbalance, 63:156
 canine tumors, 62:29
 constitutional chromosome changes, 61:50
 cytogenetic changes in stromal sarcoma, 63:47
 cytogenetic study of lymphocytes of cancer patients, 63:158
 cytogenetics in cancer, 63:158-159
 cytogenetics of metastases, 63:159
 cytogenetics of fibroadenomas, 63:32, 156-157
 fibroadenomas, 63:32, 156-157
 FISH in fibroadenomas, 63:32
 FISH studies in sarcoma, 63:47
 improved method for metaphases, 63:107
 LOH on chromosome 17, 63:160
 multiclonality in cancer, 63:157
 phyllodes tumor, 60:74
 p53 changes in cancer, 63:117
 SCE levels in patients with cancer, 61:142
 SOD in normal and tumor tissues, 59:26
 SOD-1 gene, 59:26
 stromal sarcoma, 63:47
 t(11;19) in sarcoma, 63:47
 11q13 and DNA amplification in cancer, 63:155
Burkitt lymphoma
 chromosome changes in, 60:206
 chromosome 13, 60:206
 genetic events and cell proliferation, 64:42
 in immune compromised patients, 64:42
 translocations in, 60:206
Cancer
 Bartholin gland, 61:26
 chromosome registry, 59:105
 cytogenetic limning of events, 59:107
 fragile sites and cancer breakpoints, 61:213
 familial skin cancer, 61:1
 hypomethylation and chromosome instability, 63:155
 mitotic spindle failure in, 62:106
 multiple skin cancer, 61:1
 of adrenal, 61:96
 of lung, 59:1
 of stomach, 58:79; 61:39
 somatic cell genetics, 59:107

- Canine tumors
 - mammary, 62:29
 - r(X) and +5 in tumor, 62:29
- Carcinoid tumor
 - chromosomes in, 59:220
 - gastric, 59:220
- Cartilaginous tumors
 - cytogenetic findings, 63:126
- Cat
 - chromosome alterations in leukemia, 64:149
 - leukemia, 64:149
 - oncogenesis in leukemia, 64:149
- Cell lines
 - Chinese hamster, 62:81
 - chromosome changes in human, 59:39
 - EBV transformed lymphoblastoid cell lines, 60:164
 - embryonal rhabdomyosarcoma, 61:214
 - human, 59:39
 - immortalized, 59:39
 - melanoma, 62:111
 - multidrug resistant, 60:14
 - neuroblastoma, 59:119
 - ovarian carcinoma, 60:14
 - squamous lung cancer, 59:111
 - T-cell lymphoma, 59:199
 - uterine stromal sarcoma, 60:60
- Central nervous system
 - chromosome changes in tumors, 60:67
 - ependymomas, 60:67
 - low grade tumors, 60:67
- Centromere
 - division under fragile site conditions, 58:152
 - premature division, 58:152
- Cervical cancer
 - cell proliferation in, 63:154
 - chromosome fragility in lymphocytes, 59:173
 - chromosome 1 in, 60:214
 - constitutional chromosome changes, 61:50
 - cytogenetics of, 60:214
 - dms in, 58:134
 - effects of papillomavirus on lymphocytes, 59:173
 - in situ cancer, 59:84
 - ploidy and dms, 58:134
 - premalignant lesions, 63:153
 - p53 mutations, 63:116
 - SCE in patients with, 58:84
 - viruses and chromosomal breakpoints, 59:135
- Childhood
 - cytogenetic study in -7, 62:160
 - FISH studies in -7 syndrome, 62:160
 - monosomy 7 syndrome, 62:160
- Childhood tumors and leukemias; see Pediatric conditions
- CMMoL in, 60:190
- M2 with del(16)(q22), 59:86
- Chondroblastoma
 - benign, 58:14
 - chromosome changes in, 58:14
 - translocations in, 58:14
 - t(1;1;5;17;22) in, 58:14
- Chondrosarcoma
 - chromosome changes, 60:35
 - t(6;12) and (12;19) in, 60:35
 - 12q13 in, 60:35
- Chordoma
 - chromosomal abnormalities, 58:169; 64:95
 - sacral, 64:95
 - t(1;21) in, 58:169
 - t(2;21) in, 58:169
- Choroid plexus tumors
 - chromosome changes, 59:12
 - papilloma, 59:12
 - pediatric, 59:12
- Chromatin
 - structure in viral integration, 60:1
- Chromosome
 - breakpoints in cervical cancer, 59:135
 - fragility in cervical cancer patients, 59:173
 - fragility in fibroblasts, 60:1
 - instability in cancer patients, 60:84
 - painting, 63:106
 - 1p, 16q and 17p in Wilms tumor, 61:111
 - 2 in ANLL (M2), 58:48
 - +2 in proliferative fasciitis, 60:27
 - 3 and thrombopoiesis, 59:138
 - 5 in ALL, 61:106
 - 5 in ANLL, 58:18, 130
 - 5 in MDS following tumor surgery, 58:125
 - 6 in AML (M2), 58:181
 - 6 in mesothelioma, 59:57
 - 6 sequences, 63:110
 - 6p in ANLL, 60:93
 - 7 in ANLL, 58:18
 - 8 in ANLL, 58:18
 - 8p11 in M5, 60:180
 - 10 in gliomas, 58:109
 - 11 in malignant melanoma, 58:196
 - 11p in osteogenic sarcoma, 58:60
 - 11p13 and 11p15 in Wilms tumor, 61:111
 - 11p15 in Beckwith-Wiedemann syndrome, 58:60
 - 11p15 in giant cell tumor, 58:2, 60
 - 11q13 in ependymoma, 59:213
 - 11q21 in essential thrombocythemia, 58:105
 - 12 in ANLL, 58:18
 - 12q13 in chondrosarcoma, 60:35
 - 12q13-15 in pleomorphic adenomas of salivary glands, 58:85
 - 13 in Burkitt lymphoma, 60:206
 - 16 in ANLL, 58:18, 29
 - 16 in M4, 58:29, 130
 - 18 and MDS and secondary leukemia, 63:97
 - 19 and thyroid adenomas, 60:23
 - 19q13 in thyroid adenoma, 60:99
 - 20 in MDS, 58:174
- Chromosome changes
 - at relapse after BMT for Ph+ CML, 61:183
 - chondroblastoma, 58:14
 - giant cell tumor, 58:2, 60
 - in ALL, 58:121, 60:82, 206; 61:106, 201; 62:154; 64:27, 49
 - in ANLL, 58:18, 29, 48, 71, 130, 155, 177, 181; 59:86; 60:117, 61:126, 139; 62:154; 64:93

- in ANLL (children), 58:155
- in chondrosarcoma, 60:35
- in chordoma, 58:169
- in clear cell sarcoma, 64:101, 104, 107
- in CML, 58:92, 96, 165, 212; 59:5; 61:104, 183, 63:37
- in colorectal cancer, 62:32, 191; 64:183
- in dermatofibrosarcoma protuberans, 58:52
- in gastric cancer, 58:79
- in gliomas, 58:109; 59:12
- in hepatocellular cancer, 58:191
- in leiomyosarcoma, 62:43
- in lung cancer, 59:1
- in lymphoma, 58:35, 100; 59:62, 60:206; 61:31, 62:208
- in MDS, 58:76, 125, 174; 61:162; 62:154; 64:12
- in myelofibrosis, 58:89; 61:6
- in M4, 58:130, 204
- in M4 with Ph and inv(16), 58:29
- in M5, 58:71
- in oncocytoma, 61:61, 108
- in pediatric CNS tumors, 59:12; 64:75
- in pleomorphic adenomas, 58:85
- in prostate cancer, 61:165
- in rat transformed fibroblasts, 58:39
- in RAEB, 58:76, 125; 59:9; 64:12
- in rhabdomyosarcoma, 58:210; 60:135
- in secondary ANLL, 58:18
- in Sézary syndrome, 58:100
- in soft tissue tumors, 58:52, 135; 60:147, 170
- in squamous cell cancer, 59:73
- in testicular tumors, 61:67; 64:21
- in Wilms tumor, 59:104; 61:111
- 11q and/or 12q in melanoma, 64:118
- Chronic Lymphocytic Leukemia (CLL)**
 - application of FISH, 63:62
 - B-cell, 60:131; 62:108
 - chromosome changes, 60:131; 62:108
 - t(1;19) in, 60:131
 - +8 in, 62:108
- Chronic Myelocytic Leukemia (CML)**
 - allogeneic BMT, 61:152, 183
 - application of FISH, 63:62
 - bcr breakpoint in Spanish CML cases, 60:108
 - bizarre blasts, 58:92
 - blast crisis with inv(16) and eosinophilia, 62:134
 - blastic phase, 58:92; 61:152
 - BMT in Ph+ CML, 61:152, 183
 - chromosome changes and BMT, 58:143; 61:152
 - chromosome changes in, 58:92, 96, 143; 60:96; 61:152, 183; 62:154, 63:37
 - chromosome 3, 61:42
 - complex Ph translocation, 63:52
 - del(7) with prolonged course, 58:212
 - del(7)(p11p15) in Ph+ CML, 64:142
 - disappearance of clone with del(7) and Ph after therapy, 64:174
 - effects of interferon and cytosine arabinoside on karyotype, 64:174
 - FISH detection of i(17q), 62:140
 - i(17q) detection by FISH, 62:140
 - inv(16) and eosinophilia in myelomonocytic transformation, 61:197; 62:134
 - karyotype at relapse, 61:183
 - karyotypic and clinical progression after 30 years, 60:96
 - LOH of D3S2 locus in, 61:42
 - myelomonocytic transformation, 61:197
 - M4 and inv(16) complicating Ph+ CML, 59:35
 - near-triploid transformation, 58:92
 - normal cytogenetic picture after α -interferon, 58:165
 - Ph+, bcr-, 61:11
 - Ph- cells after BMT, 58:143; 61:152
 - relapse after BMT, 61:152, 183
 - remission of blastic phase, 58:165
 - t(2;3)(p13;q26) in accelerated phase, 59:95
 - t(3;17)(q26;q22) in CML, 60:90
 - t(6;8) in Ph+ CML, 61:104
 - t(6;21) in Ph+ CML, 60:210
 - t(8;21)(q22;q22) in blastic crisis of Ph+ CML, 58:96
 - t(9;11)(p22;q23) in blastic phase, 63:37
 - Y-bodies after BMT, 58:143
 - 3p- in, 61:42
 - 20q- in, 62:75
- Chronic Myelomonocytic Leukemia (CMMoL)**
 - chromosome changes in blood cells, 59:167
 - cytogenetic findings, 61:126, 162, 179; 64:12
 - i(14q) in CMMoL following RAEB, 64:97
 - in child, 60:190
 - leukemic evolution, 61:162, 174
 - Ph chromosome in, 59:161
 - trisomy 14q in, 64:91
 - t(1;7)(p11;p11) and survival, 60:53
 - t(13;14) in, 60:190
 - 20q- in, 58:174
- Ciliary body tumor**
 - adenoma of, 63:177
 - cytogenetics of, 63:177
 - pathology of, 63:177
- Clear cell sarcoma**
 - chromosome changes, 60:176; 64:101, 104, 107
 - malignant melanoma of soft parts, 60:176
 - significance of chromosome changes, 64:104
 - t(12;22)(q13;q13) in, 64:101, 104, 107
 - +8 in, 64:107
- Colorectal Cancer (and Tumors)**
 - anomalies of familial and sporadic, 63:118
 - APC gene in familial polyposis, 63:124
 - APC locus detected by PFGE, 63:123
 - BCE1/pS2 gene in, 63:120
 - chromosome changes, 59:103; 62:32, 191
 - chromosome 7 in adenomas, 63:122
 - chromosomes 13 and 17 and RB1 and p53, 63:123
 - constitutional chromosome changes, 61:50
 - cytogenetics and survival, 63:122
 - genetic alterations, 59:103
 - t(13q;17p) and 5q- in, 62:191
 - t(17;20) in adenocarcinoma, 64:183
 - 17p, 18q and 5q in, 59:103
- Congenital leukemia**
 - ALL (L1), 62:124
 - chromosome changes in, 62:124; 63:56
 - karyotypic evolution, 62:124, 63:56

- review, 63:56
- Constitutional changes
 - balanced translocations in cancer patients, 61:50
 - in cancer patients, 61:50
 - t(8;13) in a patient with lymphoma, 59:80
- Craniopharyngioma
 - chromosome changes, 59:12; 60:73, 212
 - pediatric, 59:12; 60:73
- Cytogenetic changes
 - after relapse of BMT in Ph+ CML, 61:183
 - chondroblastoma, 58:14
 - giant cell tumor, 58:2, 60
 - in ALL, 58:121, 60:82, 206; 61:106, 201; 62:154; 64:27, 49
 - in ANLL, 58:18, 29, 48, 71, 130, 155, 177, 181; 59:86; 60:117, 61:126, 139; 62:154; 64:93
 - in ANLL (children), 58:155
 - in chondrosarcoma, 60:35
 - in chordoma, 58:169
 - in clear cell sarcoma, 64:101, 104, 107
 - in CML, 58:92, 96, 165, 212; 59:5; 61:104, 183, 63:37
 - in colorectal cancer, 62:32, 191; 64:183
 - in dermatofibrosarcoma protuberans, 58:52
 - in gastric cancer, 58:79
 - in gliomas, 58:109; 59:12
 - in hepatocellular cancer, 58:191
 - in leiomyosarcoma, 62:43
 - in lung cancer, 59:1
 - in lymphoma, 58:35, 100; 59:62, 60:206; 61:31, 62:208
 - in MDS, 58:76, 125, 174; 61:162; 62:154; 64:12
 - in myelofibrosis, 58:89; 61:6
 - in M4, 58:130, 204
 - in M4 with Ph and inv(16), 58:29
 - in M5, 58:71
 - in oncocyoma, 61:61, 108
 - in pediatric CNS tumors, 59:12; 64:75
 - in pleomorphic adenomas, 58:85
 - in prostate cancer, 61:165
 - in rat transformed fibroblasts, 58:39
 - in RAEB, 58:76, 125; 59:9; 64:12
 - in rhabdomyosarcoma, 58:210; 60:135
 - in secondary ANLL, 58:18
 - in Sézary syndrome, 58:100
 - in soft tissue tumors, 58:52, 135; 60:147, 170
 - in squamous cell cancer, 59:73
 - in testicular tumors, 61:67; 64:21
 - in Wilms tumor, 59:104; 61:111
 - 11q and/or 17q in melanoma, 64:118
- Deletions
 - del(2)(p13) in MDS, 59:97
 - del(6) in AML (M2), 58:181
 - del(7) in CML with long course, 58:212
 - del(7)(p11p15) in CML, 64:142
 - del(7q) in squamous cell cancer of head and neck, 59:73
 - del(9) in splenomegaly, 58:201
 - del(11)(q23) in lymphoma, 58:36
 - del(12)(p12) in ANLL, 58:18
 - del(16)(q22) in ANLL, 58:18
 - del(16)(q22) in M2 with eosinophilia, 58:86
 - del(20) in MDS, 58:174
 - in ALL, 59:191
 - in ANLL, 60:117
 - in childhood ANLL, 58:155
 - in immortal human cell lines, 59:39
 - in lung cancer, 59:1
 - in lymphoma, 59:68
 - in MDS and ANLL, 62:27; 64:12
 - interstitial of 9 in splenomegaly, 58:201
 - in gastric cancer, 58:79
 - in gliomas, 58:109
 - t(15;21) and 5q- in AML, 61:139
 - 5q- in ALL, 61:201; 63:89
 - 5q- in colorectal cancer, 62:191
 - 5q- in MDS, 62:100, 64:12
 - 5q- in thrombocythemia, 61:93
 - 9q- and +21 in M2, 64:91
 - 11q in essential thrombocythemia, 58:105
 - 12p- in AML, 62:47
 - 20q- in hematologic disorders, 62:75
- Dermatofibrosarcoma protuberans
 - chromosome changes in, 58:52; 60:170
 - ring chromosome in, 58:52; 60:170
- Desmoplastic tumor
 - cytogenetic changes in, 64:189
 - small cell, 64:189
- Diamond-Blackfan Anemia
 - leukemia in, 63:70
 - pentasomy 21 in leukemia of, 63:70
- DNA studies
 - biotinylated probe in neuroblastoma, 58:55
 - DNA fingerprint analysis in bladder tumors, 61:53
 - DNA sequences in CHO *aprt* locus, 64:69
 - ETS2 in ANLL, 58:71
 - extraction of DNA from fixed cells, 59:217
 - in Beckwith-Wiedemann syndrome, 58:66
 - in germ cell tumors of testis, 61:67
 - in lymphoma (MALT), 58:35
 - in lymphoma with t(14;18), 59:68
 - in melanoma cell lines, 62:111
 - in mesothelioma, 60:8; 62:171
 - in multidrug resistant cancer cell line, 60:14
 - in pleomorphic adenomas (INT1 and GLI), 58:85
 - in rat transformed fibroblasts, 58:39
 - in T-cell lymphoma, 59:199
 - methylation in viral integration, 60:1
 - of chimeric gene in AML with t(8;21), 63:81
 - of *myb* in M2 with 6q-, 58:181
 - Southern blot analysis of genes, 62:1
- Double minute chromosomes (dms)
 - in carcinoma of cervix, 58:134
 - in glioblastoma, 64:75
 - in gliomas, 58:109
 - in insulinoma of MEN1, 63:17
 - in neuroblastoma cell lines, 59:128
- Duplication
 - paternal 11p15 in Beckwith-Wiedemann syndrome, 58:66
 - 11p15 in Beckwith-Wiedemann, 58:66
- Dyskeratosis Congenita
 - bleomycin-induced G₂ chromatid breakage, 60:31
 - families of, 60:31
 - heterozygote detection, 60:31

Editorials

- chromosome instability, 60:84
- clonal selection, 59:79
- medicine and science, 62:92
- new format of CGC, 58:1
- screening for cancer, 60:188

Endodermal sinus tumor; see Testes

Endometrial tumors; see Uterus

Eosinophilia

- associated chromosome changes, 58:29, 204
- bone marrow, 58:29, 204
- lack of in M2 with del(16)(q22), 59:86
- in M4, 58:29, 204
- inv(16) in myelomonocytic transformation of Ph + CML, 61:197
- with inv(16) and Ph in M4, 58:29

Ependymomas

- anaplastic, 59:12, 60:67
- chromosome changes, 58:116; 59:12, 213; 60:67; 61:193
- karyotypes, 58:116; 59:12, 213; 60:67; 61:193; 63:177
- low-grade, 60:67
- pediatric, 59:12, 213
- suppressor gene on chromosome 22, 61:193
- t(11;17) in, 59:213

Ewing sarcoma

- chromosome translocation 11;22, 59:104
- cloning of t(11;22), 63:162
- loss of interferon genes in progression, 63:166
- new diagnostic probes on 11q24-25, 63:162
- osteosarcomatous features in cell lines, 63:165
- t(11;22) and del(1)(p21), 63:165

Familial cancer

- cytogenetic and molecular studies of renal cancer, 63:25
- renal cell carcinoma, 63:25

Family studies

- heterozygote detection, 60:31
- in dyskeratosis congenita, 60:31

Fanconi anemia

- leukemia in, 58:206, 209
- preleukemia in, 58:206, 209

Fibroblasts

- chromosomal fragility, 60:1
- chromosome changes in malignant transformation (rat), 58:39
- chromatin structure in viral integration, 60:1
- cultures from patients with basal cell epithelioma, 61:74
- DNA methylation in viral integration, 60:1
- gene expression in viral integration, 60:1
- human cell lines, 59:39
- micronuclei and mutagen sensitivity, 58:186
- mutagenic sensitivity, 58:186
- rat, embryonal, 58:39
- SCE in cases with hydatidiform moles, 62:53
- UV effects on, 61:74
- viral integration, 60:1

Flow cytometry; see DNA studies

Fluorescence in situ hybridization (FISH)

- application in hematologic disorders, 63:64
- detection of i(17q), 62:140
- double fluorescence, 63:8

FISH in stromal sarcoma of breast, 63:47

FISH studies of breast fibroadenomas, 63:32

FISH study of complex Ph, 63:52

fundamentals of, 59:109; 63:105

in bladder cancer, 59:102

in BMT in mice, 64:145

in germ cell tumors, 63:8

in hematological diseases, 59:109

in leiomyomas, 62:40

in liposarcoma with large marker chromosome, 61:134

in marrow transplantation, 64:145

in MDS, 64:186

in meningioma, 64:65

in myxoid liposarcoma, 62:166

in prostatic cancer, 59:102; 62:180

in tumor analysis, 59:101-102; 63:105

i(12p) and chromosome 12, 63:8

i(17q) in CML, 62:140

metaphase chromosome structure, 63:105

new strategy for, 59:110

of abnormal X in M4, 62:130

studies in myelofibrosis, 61:6

studies in neuroblastoma cell lines, 59:128

usefulness in BMT, 64:145

+7 in thyroid tumors, 62:144

-7 syndrome, 62:160

Fourth International Workshop on Chromosomes in Solid Tumors

additional abstracts, 59:101-110

Fragile sites

and cancer breakpoints, 61:213

centromere division under fragile site conditions, 58:152

in lymphocytes, 58:24

in malignant melanoma (lymphocytes), 58:24

1p32 and 1p22 fragile sites, 58:24

Gallbladder

chromosome changes in MFH, 59:30

MFH in, 59:30

Gastric cancer

amplified c-met in, 64:170

antigen derived from BS cells, 62:1

c-ERBB-2 gene in, 63:121

carcinoid, 59:200

cytogenetic studies, 58:79; 61:39, 63:120; 64:170

karyotypes, 64:170

p53 changes in, 63:115

-Y in, 61:39

Gastrinoma

cytogenetics, 63:139

Gene(s)

AML1 gene on chromosome 21, 63:81

APC locus detected by PFGE, 63:123

canine homologs of human MYC, BCL2, IGH and TCRB, 62:9

CD44 gene and multidrug resistance, 60:14

chimeric gene from t(8;21), 63:81

CHO apt locus, 64:69

expression in viral integration, 60:1

INT2 and GLI in pleomorphic adenomas, 58:85

novel gene on chromosome 8 in AML, 63:81

- p53 as a transcription factor, 63:113
- Germ cell tumors**
 choriocarcinoma of testis, 61:67
 chromosome 12 changes in, 63:8
 extragonadal, 63:8, 149
 FISH studies in, 63:8, 149-150
 gonadal, 63:8
 i(12p) in, 63:8, 150
 marker chromosomes, 63:149
 teratoma, 61:67
 testicular, 59:54; 61:67; 63:8
 X-chromatin, sex chromosomes and ploidy in, 59:54
- Germinoma**
 brain, 59:12
 chromosomes in, 59:12
 inv(9) in, 59:14
- Giant cell tumors**
 bone, 58:2
 chromosome changes, 58:2, 60; 63:128
 review, 58:2
 telomeric fusions, 63:128
- Glioblastoma multiforme**
 chromosome changes, 58:109; 59:12; 64:75
 karyotypes in, 58:109; 59:12; 64:75
 pediatric, 59:12; 64:75
- Gliomas; see also Brain tumors**
 chromosome changes, 58:109; 59:12, 107; 60:72;
 63:175-176
 dms in, 58:109
 karyotypes in, 58:109; 59:12, 107
 LOH in, 58:107
 molecular analysis, 59:107; 63:176
 pediatric, 59:12
 +7, -22,-Y,-X in, 58:109
 -10 in malignant, 58:109
- Glucagonoma**
 cytogenetics of, 63:17
 in MEN1, 63:17
- Granulosa cell tumor**
 chromosome changes in, 60:41, 202; 61:207
 juvenile, 61:207
 ovarian, 60:41, 202; 61:207
 + (6;16) in, 60:41
 +14 in, 60:202
- Hairy Cell Leukemia (HCL)**
 chromosome changes, 62:186
 variant of, 62:186
- Hamartoma**
 chromosomes in, 60:219
 lung, 60:219
 mesenchymal, 58:141
 of liver, 58:141
 translocation at 19q13.4, 58:141
 t(3;6;14) in, 60:219
 t(11;19)(q13;q13.4) in, 58:141
- Hamster**
 Chinese, 62:81
 chromosome changes in transformation, 62:81
 transformation of cells, 62:81
- Head and Neck**
 cytogenetics of tumor, 59:73, 106
 squamous cell carcinoma, 59:73, 106
 tissue culture technique for, 63:106
- Hematologic disorders**
 cytogenetic biclonality, 62:25, 154
 FISH studies in, 63:62
 in Hong Kong, 62:154
 karyotypes in, 62:25, 154; 63:62
 20q- in, 62:75
- Hemangiopericytoma**
 cytogenetic analysis, 63:78
 meningeal, 63:78
 molecular studies, 63:78
 possible hemangiopericytic meningioma, 63:78
 tetrasomy 21, 63:78
- Hepatocellular carcinoma; also see Liver**
 chromosome 1 in, 59:105
 cytogenetic findings, 58:191; 60:45
 induced in rats, 60:45
 primary, 58:191
 rats, 60:45
 1p- and LOH in, 59:105
- Homogeneously Staining Regions (HSR)**
 in neuroblastoma cell lines, 59:128
 in Waldenström's macroglobulinemia, 61:147
- Hydatidiform moles**
 chromosome breakage, 62:53
 SCE in, 63:53
 SCE in lymphocytes of patients, 62:53
- Insulinoma**
 cytogenetics of, 63:17
 in MEN1, 63:17
- Interphase cytogenetics; see also Fluorescence in situ hybridization**
 in malignant mesothelioma, 62:171
 of paraffin sections, 62:171
- Inversions**
 in ANLL, 60:117
 inv(1) in lymphoma, 58:35
 inv(3)(q21q26) and thrombopoiesis, 59:138
 inv(3)(q21q26) in M2 with normal thrombopoiesis, 59:93
 inv(5) in childhood ANLL, 58:155
 inv(9) in germinoma, 59:14
 inv(11) in myelofibrosis, 61:6
 inv(16) and eosinophilia in Ph+ CML, 61:197; 62:134
 inv(16)(p13q22) in M4, 58:29; 59:35
 inv(X) in leiomyoma, 61:131
 review of inv(3) in hematologic disorders, 59:138
- Isochromosomes**
 i(6p) in Waldenström's macroglobulinemia, 58:89
 i(8) in ANLL, 58:18
 i(8) in gastric cancer, 58:214
 i(12p) in germ cell tumors, 63:8
 i(12p) in MFH, 60:147
 i(12p) in ovarian teratoma, 60:216; 62:58
 i(12p) in uterine mullerian tumor, 60:78
 i(12q) in childhood ANLL, 58:155
 i(13q) in adult ALL, 60:193

- i(14q) in myelodysplasia, 64:97
 - i(17q) detection by FISH, 62:140
 - i(17q) in CML, 60:96, 62:140
 - i(17q) in colorectal cancer, 62:32
 - i(17q) in lung cancer, 63:95
 - i(17q) in neuroectodermal tumor, 59:14
 - i(21) in biphenotypic leukemia, 64:56
- Karyotypic anomalies**
- at relapse of Ph + CML after BMT, 61:183
 - chondroblastoma, 58:14
 - giant cell tumor, 58:2, 60
 - in ALL, 58:121, 60:82, 206; 61:106, 201; 62:154; 64:27, 49
 - in ANLL, 58:18, 29, 48, 71, 130, 155, 177, 181; 59:86; 60:117, 61:126, 139; 62:154; 64:93
 - in ANLL (children), 58:155
 - in chondrosarcoma, 60:35
 - in chordoma, 58:169
 - in clear cell sarcoma, 64:101, 104, 107
 - in CML, 58:92, 96, 165, 212; 59:5; 61:104, 183, 63:37
 - in colorectal cancer, 62:32, 191; 64:183
 - in dermatofibrosarcoma protuberans, 58:52
 - in gastric cancer, 58:79
 - in gliomas, 58:109; 59:12
 - in hepatocellular cancer, 58:191
 - in leiomyosarcoma, 62:43
 - in lung cancer, 59:1
 - in lymphoma, 58:35, 100; 59:62, 60:206; 61:31, 62:208
 - in MDS, 58:76, 125, 174; 61:162; 62:154; 64:12
 - in myelofibrosis, 58:89; 61:6
 - in M4, 58:130, 204
 - in M4 with Ph and inv(16), 58:29
 - in M5, 58:71
 - in oncocyoma, 61:61, 108
 - in pediatric CNS tumors, 59:12; 64:75
 - in pleomorphic adenomas, 58:85
 - in prostate cancer, 61:165
 - in rat transformed fibroblasts, 58:39
 - in RAEB, 58:76, 125; 59:9; 64:12
 - in rhabdomyosarcoma, 58:210; 60:135
 - in secondary ANLL, 58:18
 - in Sézary syndrome, 58:100
 - in soft tissue tumors, 58:52, 135; 60:147, 170
 - in squamous cell cancer, 59:73
 - in testicular tumors, 61:67; 64:21
 - in Wilms tumor, 59:104; 61:111
- Kidney tumors; see Renal tumors**
- Klinefelter syndrome**
- ANLL (M5a) in, 61:99
 - chromosome changes in M5, 61:99
- Lacrimal gland**
- lymphoma, 58:35
- Large bowel cancer; see Colorectal cancer**
- Larynx**
- cancer cytogenetics, 58:198
 - squamous cell carcinoma, 58:198
- Leiomyomas**
- changes involving X in, 61:131-132
 - cytogenetics of, 59:106, 219; 61:131-132; 62:40, 62; 200; 63:131
 - esophageal, 62:43
 - FISH analysis, 62:40
 - interphase analysis, 62:40
 - interphase analysis and chromosome 12, 63:131
 - inv(X)(p22q13) in, 61:131
 - lipoleiomyoma of uterus, 62:200
 - t(7;22)(q13;q12), 59:219
 - t(12;14) in, 62:200
 - uterine, 59:106; 62:40, 200
- Leiomyosarcoma**
- abdominal, 62:43
 - chromosome changes in, 62:43, 44 (Table); 63:46 (Table), 47
 - of mesocolon, 62:43
 - of smooth muscle, 62:43
 - stromal sarcoma of breast, 63:47
 - uterine, 63:46
- Lentigo maligna**
- cell culture, 60:141
 - cytogenetic and other studies in, 60:141
 - in situ melanoma, 60:141
 - 10q26 in, 60:141
- Lipoma**
- lipoblastoma with t(3;8), 62:103
 - LRP gene not rearranged, 60:125
 - molecular studies in, 60:125
 - parapharyngeal, 64:163
 - ring in parapharyngeal lipoma, 64:163
 - t(2;12)(p23;q14) in, 63:127
 - t(8;12)(q13;q15) in, 63:171
 - t(10;12)(q25;q15) in lipoma, 64:163
 - 12q13-14 breakpoint, 60:125
- Liposarcoma**
- chromosome changes in, 60:125; 61:134; 64:111
 - chromosome 12 in well differentiated, 63:127
 - FISH studies of marker, 61:134
 - giant marker in well-differentiated, 61:134
 - LRP gene not rearranged in, 60:125
 - molecular studies in, 60:125
 - myxoid, 60:125
 - t(12;16) in LPS, 62:166
 - well-differentiated, 61:134
 - YAC in myxoid LPS, 62:166
 - YAC spanning t(12;16), 62:166
 - 12q13-14 breakpoint, 60:125
- Liver**
- cytogenetic findings in cancer, 58:191
 - hamartoma, 58:141
 - hepatocellular cancer, 58:191
 - mesenchymal hamartoma, 58:141
 - primary carcinoma, 58:191
 - +7 in focal steatosis, 63:22
- Loss of heterozygosity (LOH)**
- in Ph + CML, 61:42
 - LOH of D3S2 locus in Ph + CML, 61:42
- Lung**
- adenocarcinoma cell line with 8q23-qter tetrasomy, 63:181

- adenocarcinomas; cytogenetics, 63:180
 adenosquamous cancer, 59:1, 111; 63:95
 allele loss determined by PCR-RFLP, 63:179
 chromosome changes in, 59:1, 111; 63:95
 chromosome 5 in large cell cancer, 63:182
 D8 gene at 3p21 in cancer, 63:180
 FISH in cancer, 63:181
 genetic lesions of normal and cancerous lesions, 63:179
 hamartoma, 60:219
 lymphoma, 58:35
 squamous cancer cell lines, 59:111
 squamous carcinoma, 59:1
- Lymphocytes**
 bleomycin sensitivity, 64:133
 Burkitt type, 60:206
 chromosome changes in cancer patients, 60:86
 chromosome changes induced by bleomycin, 64:133
 chromosome fragility, 59:173
 chromosome 13 in, 60:206
 DNaseI-sensitive sites, 62:94
 fragile sites, 58:24
 in cervical cancer patients, 59:173
 in malignant melanoma, 58:24
 mutations at 3p and 11p in testicular tumor patients, 59:62
 papillomavirus effects, 59:173
 SCE in patients with cervical cancer, 59:84
 SCE in patients with hydatidiform moles, 62:53
 1p32 and 1p22 fragile sites, 58:24
- Lymphoma**
 B-cell of mucosa, 58:35
 B-cell of mucosa-associated tissue, 62:208
 cytogenetic changes, 58:35; 59:68, 199; 60:31; 62:208
 cytogenetics and molecular correlation in follicular, 59:68
 follicular and t(14;18), 59:68
 in ataxia telangiectasia, 60:158
 in United Kingdom, 61:31
 molecular studies in t(14;18), 59:68; 64:166
 mucosa associated lymphoid tissue (MALT), 58:35
 Sézary syndrome, 58:100
 T-cell from a patient with SCE, 59:199
 t(1;14)(q21;q32) in clonal expansion, 64:166
 t(8;13), constitutional in patient with, 59:80
- Malignant Fibrous Histiocytoma (MFH)**
 chromosomal changes, 59:30; 60:147, 170
 i(12p) in, 60:147
 near-haploid clones, 60:147
 of gallbladder, 59:30
 ring chromosomes, 60:170
 t(13q21q) in, 60:147
- Mammary tumors; see Breast tumors**
- Mapping**
 M1 subunit of ribonucleotide reductase on chromosome 11p15, 59:206
 rearrangements on chromosome 11p15, 59:206
- Marsupial (opossum)**
 chromosomal changes in UV tumors, 64:158
 cutaneous tumors, 64:158
 UV induced tumors, 64:158
- Melanoma, malignant**
 brain metastases, 64:118
 cell lines, 62:111
 chromosome 11 in, 58:196; 64:118
 chromosomes 3, 6 and 8 in uveal melanoma, 63:182
 cultures in, 64:118
 cutaneous, 58:24; 61:77
 cutaneous in swine, 61:77
 cytogenetic findings in, 58:196; 60:141, 176; 61:77, 111; 64:118
 EM, molecular studies, cytogenetics, etc. in cell lines, 62:111
 FISH in cell lines and tissue sections, 63:108
 fragile sites (in lymphocytes), 58:24
 lentigo maligna, 60:141
 metastatic, 64:118
 p53 in cell lines, 63:116
 soft parts, 60:176
 11q and/or 17q changes in, 64:118
- Meningioma**
 chromosome 22 in, 64:65
 chromosomes in, 59:12; 63:173-174, 64:65
 constitutional chromosome change, 61:50
 dicentric 22 in, 64:65
 DNA analysis, 63:173
 FISH studies in, 64:65
 histopathologic correlation with cytogenetics, 63:174
 loss or rearrangement of chromosome 22, 63:173
 molecular studies, 63:122
 PDGFB region in, 63:175
 pediatric, 59:12
 recurrent meningiomas; cytogenetics, 63:173
- Merkel cell carcinoma**
 cytogenetics, 63:138
 molecular studies, 63:138
- Mesothelioma, Malignant**
 chromosome 6 changes in, 59:57
 del(6q) in, 59:57
 DNA studies in, 60:8
 erratum of paper in CGC, 59:57, 1992, 61:110
 flow cytometric studies, 62:171
 karyotype ploidy in, 60:8; 62:21
 karyotypes in, 59:57; 62:171
 interphase cytogenetics, 62:171
 scheme for malignant transformation, 59:60
 study on paraffin sections, 62:171
 survival and chromosome number, 62:21
- Methods**
 analysis in hematologic disorders, 61:126
 bone marrow analysis, 61:46
 chromosome analysis in brain tumors, 58:160
 chromosome preparations in ovarian cancer, 59:210
 developments, 63:104
 direct for brain tumors, 58:160
 double (bicolor) fluorescence, 63:8
 extraction of DNA from fixed cells, 59:217
 FISH on paraffin sections, 62:171
 for solid tumors, 60:105
 G-banding and FISH, 63:107

- giant cell medium for marrow cytogenetics, 61:126
giant tumor cell medium, 61:126
in situ nick translocation, 62:150
nick translocation, microprocedure, 62:150
PMLC and quality of myeloid metaphases, 61:46
polydonor mixed lymphocyte culture media (PMLC), 61:46
use of frozen blood samples, 59:99
- Microdissection of chromosomes
study of 6q- in melanoma, 59:103
- Molecular studies
bcr studies in Ph+ CML, 61:11
canine homologs of human MYC, BCL2, IGH and TCRB genes, 62:9
chromosome 6 sequences, 63:110
DNA sequences and CHO apt locus, 64:69
elimination of extrachromosomal DNA, 59:108
ETS2 amplification in ANLL, 58:71
in AML with t(8;21), 63:81
in Beckwith-Wiedemann syndrome, 58:66
in bladder cancer, 61:53
in brain tumors, 59:106-107
in chromosome fragility, 60:1
in CML (LOH of D3S2 locus), 61:42
in congenital leukemia, 62:124
in familial RCC, 63:25
in gastric cancer, 64:170
in lipoma, 60:125
in lymphoma (MALT), 58:35
in lymphoma with t(14;18), 59:62
in MDR of a murine cell line, 59:20
in melanoma cell lines, 62:111
in multidrug resistant cancer cell line, 60:14
in myxoid liposarcoma, 60:125; 62:166
in neuroblastoma, 59:103, 119, 128
in neuroblastoma cell line, 59:119, 128
in ovarian teratomas, 62:58
in pediatric brain tumors, 59:104
in pleomorphic adenomas (INT1 and GLI), 58:85
in rat transformed fibroblasts, 58:39
in renal cancer, 63:25
in somatic cell hybrids expressing EJ/ras, 59:180
in T-ALL, 64:86
in T-cell lymphoma, 59:180
in testicular tumors, 64:21
inter-Alu-PCR of DNA, 59:102
L1 adhesion molecule and MIC5 gene, 60:20
mapping of 11q23, 59:108
molecular studies of bcr-, Ph+ CML, 61:11
monoclonal antibody and R1 and MIC5 gene, 60:20
of myb in M2 with 6q-, 58:181
PCR and microdissection of 6q-, 59:103
PCR and mRNA levels, 63:111
Ph+, bcr- CML, 61:11
restriction maps of highly methylated regions, 63:110
SOD and SOD-1 gene in breast, 59:26
telomere shortening in acute leukemia, 61:204
viral integration, 60:1
with biotinylated probe in neuroblastoma, 58:55
X-linked MIC5 gene, 60:20
11p15 loci, 59:206
- Monosomy
FISH studies in -7 syndrome, 62:160
in ANLL, 60:117
in cases with t(1;7)(p11;p11), 60:53
in childhood ANLL, 58:155
in lymphoma, 58:36
5 in MDS following tumor surgery, 58:125
5,7,21 in ANLL (secondary), 58:18
-7 in M4, 58:130
-7 syndrome in childhood, 62:160
-10 in gliomas, 58:109
-20 in ALL, 59:177
-21 in ANLL, 61:122
-Y,-1 in oncocyomas, 61:61, 108
-Y,-1 in renal tumors, 61:61, 108
- Mullerian tumors
chromosome changes, 60:78
i(12p) in, 60:78
malignant mixed, 60:78
uterine, 60:78
- Multidrug resistance
chromosome 11, 60:14
gene amplification, 59:20
in murine cell line, 59:20
linear extrachromosomal elements in, 59:20
molecular studies, 60:14
ovarian cancer cell line, 60:14
- Multiple endocrine neoplasia syndrome (MEN1)
cytogenetic studies in, 63:17
cytogenetics of tumors in, 63:17
glucagonoma in, 63:17
insulinoma in, 63:17
- Multiple endocrine neoplasia syndromes (MEN)
C-cell thyroid hyperplasia, 59:51
chromosomes in two unique clones, 59:51
cytogenetics of, 59:51
medullary thyroid cancer in, 59:51
translocations, 59:51
- Myelodysplastic syndromes (MDS)
aberration in blood cells, 59:167
application of FISH, 63:62; 64:186
biclinality in, 62:25
centromeric fusion in t(1;7), 64:186
chromosome changes, 58:76, 125, 174; 61:126, 162; 62:26, 154; 64:12
classification, 61:177
cytogenetic prognostic factors, 61:174
deletions in MDS, 62:27
double 20q- in, 58:174
evolution and chromosomes, 61:174
FISH studies of t(1;7), 64:186
i(14q) in, 64:97
loss of following tumor surgery, 58:125
MIKA and MAKa classifications, 61:174
NN, NA and AA classifications, 61:176; 62:154
Ph chromosome in, 59:161
prognosis, survival and karyotype, 64:12
RAEB, 58:76; 59:9; 61:162
SCE and cell cycle, 62:66

- survival in, 61:174
 trisomy in MDS, 62:27
 trisomy 14q in CMMoL, 64:91
 two clones: t(5;17) and 5q- in, 62:100
 2p13 in MDS, 59:97
 +8 and +11 in, 62:98
 +8 in, 62:70
 20q- in, 62:75
- Myelofibrosis (MF)**
 chromosome changes, 59:89; 61:6
 karyotypic evolution, 61:6
 Ph+ with bcr rearrangement, 59:89
 t(1;7)(p11;p11) and survival, 60:53
- Myelofibrosis with myeloid metaplasia (MMM)**
 in blast crisis, 59:138
 inv(3)(q21q26) in, 59:138
 thrombopoiesis and inv(3), 59:138
 t(1;7)(p11;p11) and survival, 60:53
- Myeloma**
 malignant and t(1;7)(p11;p11), 60:53
- Myxoma**
 cardiac, 63:73
 cytogenetics of, 63:73
- Neonatal leukemias; also see Congenital leukemias**
 cytogenetic features, 63:56 (Table)
 review, 63:56
- Neuroblastoma**
 amplified N-myc, 58:55
 cell lines, 59:119, 128
 chromosome changes in, 58:55; 59:128; 63:167
 chromosome 1 changes, 63:167-168
 control of gene expression by N-myc, 63:112
 FISH and immunohistochemistry, 63:168
 HSR and N-myc amplification, 63:169
 HSR in, 58:55
 localization of amplified N-myc, 58:55
 molecular and genetics, 59:103
 molecular pathology, 63:161
 MYCN amplification in cell lines, 59:119, 128
 prognosis: cytogenetic and molecular aspects, 63:166
 surface markers in cell lines, 59:119
 tumor suppressor gene in, 63:169
- Neuroectodermal tumors**
 chromosome changes in, 59:12
 chromosome 17, 59:12
 del(7)(q33) in, 59:14
 i(17q) in, 59:12
 translocation in, 59:14
- Oligodendrogliomas**
 chromosome changes in, 58:115; 60:72
 karyotypes, 58:115
- Oncocytoma**
 cytogenetic and molecular studies, 63:140
 cytogenetic findings, 61:61
 renal, 61:61; 63:140
 -Y,-1 in, 61:61; 108
- Oncogenes**
 activated Ha-ras-1, 62:15
 c-Ha-ras-1 as a mutagen, 62:15
 c-met in gastric cancer, 64:170
 chromosome localization (N-myc), 58:55
 EJ/ras expression in somatic cell hybrids, 59:180
 H-RAS and CALCA in Beckwith-Wiedemann syndrome, 58:66
 myb in M2 with 6q-, 58:181
 N-myc in neuroblastoma, 58:55
 oncogenes and prognosis of human tumors, 63:112
 site binding factors in myb, 63:117
- Oral cancer**
 DNA ploidy and metastasis, 63:119
- Osteogenic sarcoma**
 cytogenetic changes, 58:60
 giant cell, 58:60
 telomere association in, 58:60
 translocations in, 58:60
 11p in, 58:60
- Osteosarcoma**
 chromosome changes in, 63:129
 cytogenetic analysis of xenografted human, 63:129
 karyotype of, 60:170; 62:50
 osteosarcoma in retinoblastoma case had no p53 mutation, 64:178
 parosteal, 60:170; 62:50
 p53 mutation, 63:115; 64:178
 ring chromosomes, 60:170; 62:50
- Ovary**
 cancer cell line, 60:14
 chromosome changes in cancer, 63:146
 chromosome preparation of cancer, 59:210
 granulosa cell tumor, 60:41; 202; 61:207
 i(12p) in teratoma, 60:216; 62:58
 loss of 11p material in cancer, 63:147
 multidrug resistant cell line, 60:14
 mutated p53 on chromosome 17 in cancer, 63:113
 primary cancers, 63:146
 suppressed malignant phenotype and CD44 gene, 60:14
 teratoma, 60:216; 62:58
 tumors, 59:210; 61:207
 t(6;16) in granulosa cell tumor, 60:41
- Paraganglioma**
 LOH of 11q, 63:139
 predisposing locus, 63:139
- Parotid Gland**
 chromosome changes in cancer, 61:158
 metastatic carcinoma, 61:158
 mucoepidermoid carcinoma, 61:158
- Pediatric conditions**
 brain tumors, 59:12, 104
 central nervous system tumors, 59:12
 chromosomes in brain tumors, 59:12
 M2 with del(16)(q22) without eosinophilia, 59:86
- Penis**
 cytogenetic changes in cancer, 64:139
 squamous cell carcinoma, 64:139
- Peripheral neuroepithelioma**
 t(11;22) and del(1)(p21), 63:165
- Philadelphia (Ph) chromosome**

- complex Ph translocation in CML, 63:52
FISH studies of complex Ph, 63:52
in blastic phase of CML, 58:92, 96; 165
in CML, 61:126
in myelodysplastic syndromes, 59:161
in M4 with inv(16), 58:29
marrow fibrosis associated with, 59:89
myelofibrosis and bcr rearrangement, 59:89
Ph positive, bcr negative CML, 61:11
Ph⁻ cells in Ph⁺ CML after BMT, 58:143
+5 in Ph⁺ ANLL, 61:216
- Phyllodes tumor
breast, 60:74
t(6;12)(q23;q13) and t(10;16)(q22;p11), 60:74
- Pineocytoma
cytogenetics, 64:127
-22 in, 64:127
- Ploidy
in germ cell tumors, 59:54
- Polycythemia Vera
20q- in, 62:75
- Premature Chromosome Condensation
use in analysis of radiation induced chromosome changes, 59:103
use for chromosomal aberrations, 63:106
- Proliferative fascitis
+2 change, 60:27
- Prostate cancer
cell cultures, 62:180; 63:151
chromosome instability, 61:165
chromosome 9 variants in, 63:152
cytogenetic changes, 61:165; 62:183; 63:151-152
FISH in, 59:102; 62:181
interphase cytogenetics, 63:151-152
- Rat
chromosome changes in neoplastic progression, 58:39
embryonal fibroblasts, 58:39
neoplastic progression, 58:38
transformation of fibroblasts, 58:39
- Refractory Anemia; see MDS
chromosome changes in blood cells, 59:167
chromosomes in, 58:125; 174; 61:126, 162, 179; 64:12
evolution, 61:174
loss of 5 in, 58:125
t(1;7)(p11;p11) and survival, 60:53
+8 in, 62:70
20q- in, 58:174
- Refractory Anemia with Excess of Blasts (RAEB)
chromosome changes in blood cells, 59:167
chromosome 18 in, 63:97
chromosomes in, 58:125; 174; 61:126, 162, 179; 64:12
evolution, 61:174
inv(3)(q21q26) in, 59:138
loss of 5 in, 58:125
thrombopoiesis and chromosome 3, 59:138
t(1;7)(p11;p11) and survival, 60:53
t(8;21) in, 58:76
+8 in, 62:70
+14 in, 59:9
20q- in, 58:174
- Refractory Anemia with Excess of Blasts in Transformation (RAEB-T)
chromosome changes, 61:162, 180, 210; 64:12
chromosomes in RAEB-T and AML after RAEB, 61:211
leukemic evolution, 61:162, 174, 210
+8 and +11 in, 62:98
+8 in, 62:70
-22 in transformation, 61:210
- Refractory Anemia with Ring Sideroblasts (RARS); see MDS
chromosome changes in blood cells, 59:167
chromosomes in, 58:125; 61:126, 179; 64:12
evolution, 61:174
loss of 5 in, 58:125
+8 in, 62:70
- Renal tumors
chromosome changes in nonneoplastic tissue, 63:141
chromosomes, clinical stages and histology, 64:30
chromophobe cell carcinoma, 61:61
constitutional t(3;8) and familial RCC, 63:25
cytogenetic and molecular studies in RCC, 63:25
familial RCC, 63:25, 110, 142
family with RCC and polycystic kidney disease, 63:143
FISH studies in RCC, 63:25
genetic fingerprint analysis in patients with RCC, 43:14
oncocyctomas, 61:61
papillary and nonpapillary, 59:104
prognosis and chromosome changes in RCC, 63:141
pseudoautosomal region (locus of suppressor gene), 59:104
restriction map of breakpoint in familial RCC, 63:110
t(X;1)(p11.2;q21) in renal adenocarcinoma, 63:100, 143
Wilms, 60:102; 61:111
Y and X chromosome in papillary tumors, 59:104
-Y,-1 in oncocyctomas and carcinoma, 61:61
- Retinoblastoma
bilateral, 64:178
cytogenetics of, 63:1; 64:1
family linkage, 64:1
genetics of, 63:1; 64:1
RB1 gene, 63:1; 64:1
osteosarcomas in, 64:178
review on, 63:1; 64:1
- Rhabdoid tumor
brain, 59:12
chromosomes in, 59:12
- Rhabdomyosarcoma
alveolar, 60:135
chromosome changes in, 58:210; 60:135, 198; 61:214; 63:164
embryonal, 58:210; 60:198; 61:214
p53 in siblings with brain tumor and rhabdomyosarcoma, 63:114
translocation in embryonal, 61:214
t(8;11)(q12-13;q21) in, 58:210
t(11;22) and del(22)(q12), 63:164
with high chromosome number, 60:198
12q13 in, 60:135
- Ring chromosomes
as sole change in tumors, 60:170

- in dermatofibrosarcoma protuberans, 58:52; 60:170
 - in giant cell tumor, 58:5
 - in lipoma, 64:163
 - in MHF, 60:170
 - in neuroblastoma cell line, 59:128
 - in pleomorphic xanthoastrocytoma, 60:152
 - in soft tissue tumors, 60:170
 - r(X) in M4, 62:130
- Salivary glands
 - adenomas, 58:85
 - chromosome changes in cancer, 61:158
 - chromosome changes in pleomorphic adenomas, 58:85
 - genetic changes in tumors, 63:118
 - mucoepidermoid carcinoma of parotid, 61:158
- Sarcoma
 - chondrosarcoma, 60:35
 - MFH, 59:30
 - osteogenic, 58:60
 - rhabdomyosarcoma, 58:210; 60:198; 61:214
- Secondary leukemia
 - chromosome changes, 58:18; 125; 63:97
 - chromosome 18, 63:97
 - monosomy (5,7,21) in, 58:18
 - translocation in, 58:18
 - trisomy (8,11,15) in, 58:18
- Seminoma
 - bilateral, 63:147
 - cytogenetics of, 63:147; 64:21
- Sex chromosomes
 - in germ cell tumors, 59:54
- Sézary syndrome
 - cytogenetic findings, 58:100
 - large cell transformation, 58:100
- Sister chromatid exchange (SCE)
 - in bone marrow of MDS and ANLL, 62:66
 - in hydatidiform moles and patients, 62:53
 - in patients with breast cancer, 61:142
 - in patients with cervical cancer, 59:84
- Skin
 - basal cell epithelioma patients, 61:74
 - cancer and UV induced changes, 60:111
 - cancer cytogenetics, 58:198; 60:111
 - melanoma in swine, 61:77
 - multiple, 61:1
 - pedigrees in familial cancer, 61:1
 - squamous cell carcinoma, 58:198
- Small intestine
 - lymphoma, 58:35
- Soft tissue tumors
 - chromosome changes in, 58:52; 62:103
 - chromosome instability, 59:105
 - clinical relevance of cytogenetics in tumors, 63:125
 - cytogenetic classification of tumors, 63:125
 - cytogenetics of, 63:125
 - dermatofibrosarcoma protuberans, 58:52
 - fibroxanthoma of stomach, 63:119
 - lipoblastoma, 62:103
 - lipoleiomyoma, 62:200
 - liposarcoma, 64:111
 - MFH, 59:30; 60:147
 - neuroblastoma, 58:55
 - phyllodes tumor of breast, 60:74
 - rhabdomyosarcoma, 58:210; 60:135, 198; 61:214
 - ring chromosomes, 60:170
- Somatic cell hybrids
 - chromosome losses in, 59:180
 - EJ/ras expression in, 59:180
 - tumorigenic revertants, 59:180
- Splenomegaly
 - del(9) in, 58:201
- Squamous cell carcinoma (SCC)
 - chromosome changes, 58:198; 59:73; 64:139
 - del(7q) in, 59:73
 - der(16) in (skin), 58:198
 - head and neck, 59:73, 106
 - larynx, 58:198
 - oral, 63:119
 - penis, 64:139
 - skin, 58:198
- Stomach
 - cancer, 58:79
 - fibroxanthoma, 63:119
 - i(8q) in, 58:214
 - long survival with i(8q), 58:214
 - lymphoma, 58:35
- Stomach cancer; see Gastric cancer
- Superoxide dismutase (SOD)
 - activity in normal and tumor breast tissues, 59:26
 - gene methylation, 59:26
 - SOD-1 gene, 59:26
- Swine
 - cytogenetics of cutaneous melanoma, 61:77
 - malignant melanoma, 61:77
 - melanoma cell lines, 61:77
- Synovial sarcoma
 - yac clone bridging t(X;18), 63:130
- T-cells
 - ALL, 58:121; 64:86
 - DNAseI-sensitive sites, 62:94
 - lymphoma from a patient with SLE, 59:199
 - lymphoma in United Kingdom, 61:31
 - T-ALL cell line with t(8;14), 64:86
- Telomere
 - shortening in acute leukemia, 61:204
 - shortening in ALL, 61:204
 - shortening in AML, 61:204
- Telomeric fusion (association)
 - evolving to rings, 60:152
 - in brain tumor, 60:152
 - in giant cell tumors, 58:2, 60
 - in glioblastoma, 64:75
 - in osteogenic sarcoma, 58:60
 - in pleomorphic xanthoastrocytoma, 60:152
 - 4p,8p,11p,14p,17p,17q,20q in osteogenic sarcoma, 58:60
 - 11p,13p,15p,18p,19p and 21p in giant cell tumors, 58:2
- Teratoma
 - biology of, 62:58
 - chromosome changes in, 60:216; 62:58; 64:21

- i(12p) in ovarian, 60:216; 62:58; 64:21
 malignant, 62:58
 molecular studies, 62:58
 ovarian, 60:216; 62:58
 testicular, 64:21
- Testes**
 choriosarcoma, 61:67
 chromosome 12 changes in germ cell tumors, 63:8; 150; 64:21
 chromosomes 1, 12 and 15 in germ cell tumors, 63:148
 cytogenetic studies in germ cell tumors, 59:54; 61:67; 63:148; 64:21
 FISH studies in, 63:8, 150
 germ cell tumors of, 59:54; 61:67; 63:8; 64:21
 germ line mutations, 59:62
 high resolution banding in patients with, 59:62
 i(12p) in germ cell tumors, 63:8; 150
 molecular studies in tumors; 64:14
 seminoma, 63:147; 64:21
 teratoma, 61:67
 uniparental origin of i(12p) in germ cell tumors, 63:150; 64:21
 X-chromatin, sex chromosome and ploidy in tumors, 59:54
- The Third Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumors**
 abstracts, 63:104-183
 Editorial Comment, 63:102
- Thrombopoiesis**
 abnormal, 59:138
 chromosome 3 and, 59:138
 review of cases with inv(3) and t(3;3), 59:138
 3q21q26 and abnormal, 59:138
- Thrombocythemia**
 chromosome 11 changes, 58:105
 essential, 58:105; 61:93
 5q-, 61:93
 11q21 in, 58:105
 20q- in, 62:75
- Thyroid**
 adenomas, 60:23; 99; 63:134, 137
 adenomas: 3 cytogenetic subgroups, 63:136
 C-cell hyperplasia, 59:51
 cell line from papillary cancer, 63:138
 chromosome 19 and adenomas, 60:23; 99
 cytogenetic changes in neoplasm, 59:51; 60:23; 99; 63:133-135, 137
 cytogenetics of benign tumors, 63:133-134
 cytogenetics of papillary carcinomas, 63:134
 medullary cancer in MEN
 multinodular goiters: cytogenetics, 63:135
 oncogene activation and chromosome changes, 63:133
 oncogene RET changes in papillary cancer, 63:137
 p53 mutation in tumors, 64:114
 translocation in, 59:51; 60:23, 99
 t(2;3) in follicular adenoma, 64:38
 t(2;3)(q12;p24) in follicular adenomas, 63:136
 unique chromosome changes, 59:51; 60:23
 +7 in tumors, 62:144
- Translocations**
 dic(3;7)(q11;q36) in M2, 60:119
 dic(6;16)(q11;q22) in granulosa cell tumor, 60:41
 dic(7;8)(q11;q24) in leiomyosarcoma, 62:43
 dic(14;19)(p11;p11) in leiomyosarcoma, 62:43
 dic(Y;21)(q11.2;p13) in renal oncocytoma, 61:63
 dic(Y;22)(q11.2;p11) in renal oncocytoma, 61:63
 in ALL, 59:191
 in ataxia telangiectasia, 60:158
 in human cell lines, 59:39
 in malignant disease in ataxia telangiectasia, 60:161
 in osteogenic sarcoma, 58:60
 Robertsonian in cancer patients, 61:50
 survival in cases with t(1;7)(p11;p11) 60:53
 t(1;1)(p22;q23) in granulosa cell tumor, 61:207
 t(1;1)(p34;q11) in lung cancer, 59:1, 3
 t(1;1;5;17;22)(q42;p32;p13;q12-21;q12-13) in chondroblastoma, 58:14
 t(1;2)(p34;p14) in glioma, 58:112
 t(1;3)(p33;p21) in renal cancer, 64:30
 t(1;3)(p36;q21) in ANLL, 64:80
 t(1;3)(q21;p36) in astrocytoma, 59:14
 t(1;3)(q21;q26) in ALL (L2), 62:155
 t(1;3)(q25;p21) in refractory anemia, 64:14
 t(1;3;7)(p22;p23;q11) in M1 ANLL, 61:24
 t(1;4)(p13;q21) in RAEB, 61:162
 t(1;4)(p22;q13) in SCC of head and neck, 59:73
 t(1;4)(p22;q21) in leiomyosarcoma, 62:43
 t(1;4)(p36.2;q21) SCC of head and neck, 59:73
 t(1;4)(q21;p12) in Ph+ CML, 61:198
 t(1;5)(p11;q33) in ALL, 61:128
 t(1;5)(q21;q35) in MDS, 62:26
 t(1;5)(q21;q35) in renal cancer, 64:30
 t(1;5;10)(p34.3;q13.3;q22.1) in hairy cell leukemia, 62:186
 t(1;6)(p11;q11) SCC of head and neck, 59:73
 t(1;6)(p36;q21) in ANLL (M4), 59:48
 t(1;6)(q21;p13) in CML, 62:15
 t(1;6)(q24;p25) in myelofibrosis, 61:6
 t(1;6)(q32;q27) in ALL, 63:89
 t(1;7)(p11;p11) and survival, 60:53
 t(1;7)(p11;p11) in MDS, 62:26
 t(1;7)(p13;q11.2) in cancer of parotid, 61:158
 t(1;7)(p36;p15) in T-cell lymphoma cell line, 59:199
 t(1;7)(q31;q21) in M2 ANLL, 61:24
 t(1;7)(q41;p13) in M2 ANLL, 61:24
 t(1;9)(p11;p13) in renal cancer, 64:30
 t(1;9)(p22;p13) in colorectal cancer, 62:192
 t(1;9)(p32;q12) in lymphoma, 61:33
 t(1;9)(q11;p13) in T-cell lymphoma cell line, 59:199
 t(1;9)(q25;p24) in Mullerian tumor, 60:78
 t(1;9;10)(q11;q11;q26) in glioma, 58:112
 t(1;10)(p22;q22) in M3 ANLL, 61:24
 t(1;10)(q11;p15) in metastatic melanoma, 64:122
 t(1;11)(p13;q23) in adrenal cancer, 61:96
 t(1;11)(p36.31;p11.2) in embryonal rhabdomyosarcoma, 61:214
 t(1;11)(q12;q23) in RARS, 61:179
 t(1;11)(q22;p11) in lung cancer cell line, 59:111
 t(1;11)(q23;q21) in lentigo maligna, 60:141
 t(1;11)(q31;q21) in neuroectodermal, 59:14
 t(1;11;21)(q23;q23;q22) in childhood ANLL, 58:155

- t(1;12)(p11;q13) in liposarcoma, 64:111
 t(1;12;16)(p11;q13;q11) in liposarcoma, 64:111
 t(1;12)(p13;q21) in ALL, 61:201
 t(1;12)(p36;q11) in glioma, 58:112
 t(1;12)(q11;q13.3) in ependymoma, 61:193
 t(1;12)(q13;q11) in ALL (L1), 62:155
 t(1;12)(q23;q24) in metastatic melanoma, 64:122
 t(1;12)(q42;q13) in liposarcoma, 64:111
 t(1;14)(p22;q11) SCC of head and neck, 59:73
 t(1;14)(p22;q32) in lymphoma (MALT), 58:35
 t(1;14)(q11;p11) in astrocytoma, 59:14
 t(1;14)(q44;q22) in cancer of lung, 63:95
 t(1;15)(q21;q22) in lymphoma, 61:33
 t(1;16)(p11;p11) in liposarcoma, 64:111
 t(1;16)(q21;p11) in lymphoma, 61:33
 t(1;16)(q21;q24) in Ph + CML, 60:96
 t(1;16)(q22;p11) in liposarcoma, 64:111
 t(1;16)(q25;q23) in RAEB-t, 64:15
 t(1;16)(q32;p11.2) in MFH, 59:30
 t(1;17)(p11;q25) in melanoma cell line, 62:111
 t(1;18)(p12;q11) in Wilms tumor, 60:102
 t(1;18)(q11;p11) in myelofibrosis, 61:6
 t(1;19)(p35-36.1;q13) in thyroid adenoma, 60:23
 t(1;19)(q23;p13) in ALL, 59:191; 61:106
 t(1;19)(q23;p13) in ALL (L1), 62:155
 t(1;19)(q23;p13) in Mullerian tumor, 60:78
 t(1;19)(q25;q13.3) SCC of head and neck, 59:73
 t(1;19)(q25;q13.4) in rhabdoid tumor, 59:14
 t(1;21)(q12;q22) in liposarcoma, 64:111
 t(1;21)(q21;q22) in chordoma, 58:169
 t(1;22)(p12;q11) in astrocytoma, 59:14
 t(1;22)(q11;q13.3) in pleomorphic xanthoastrocytoma, 60:152
 t(1;22)(p31;q13) in cancer of Bartholin gland, 61:26
 t(2;3)(p13;q26) in Ph + CML in accelerated phase, 59:95
 t(2;3)(q12-13;q24-25) in thyroid adenoma, 64:38
 t(2;3)(q21;p14) in renal cancer, 64:30
 t(2;3)(q21;q27) in lymphoma, 59:68
 t(2;3)(q31;p11) in RAEB, 61:162
 t(2;3)(q31;p25) in ALL, 64:50
 t(2;4)(p23;q35) in M2, 58:48
 t(2;4)(q37;q21) in ANLL (M2), 59:48
 t(2;7)(p13;q36) in M4, 60:120
 t(2;7)(p24-25;p13) in ANLL (M4), 59:48
 t(2;8)(q31;p23), in ANLL (M4), 59:48
 t(2;9)(p11;q11) in SCC of head and neck, 59:73
 t(2;9)(p12;p23) in ALL with t(4;14), 60:82
 t(2;9)(p12;p23) in renal cancer, 64:30
 t(2;11)(p21;q23) in ALL, 63:89
 t(2;12)(q21;q13) in craniopharyngioma, 60:212
 t(2;12)(q31;p12) SCC of head and neck, 59:73
 t(2;12)(q32-33;q15) in pleomorphic adenomas, 58:86
 t(2;13)(q32;p12) in chondroblastoma, 58:14
 t(2;14)(p13;q32) in ALL, 58:121
 t(2;14)(q21;q32) in ANLL (M1), 59:48
 t(2;14;12)(p13;q32;q11) in ALL, 58:123
 t(2;15)(q35;q15) in cancer of parotid, 61:158
 t(2;16)(p11.2;p11.2) in ALL, 64:60
 t(2;16)(q21;q22) in CLL, 62:108
 t(2;17)(q23;p13.3) in embryonal rhabdomyosarcoma, 61:214
 t(2;19)(q34;q13.3) in craniopharyngioma, 59:14
 t(2;21)(q11;q22) in chordoma, 58:169
 t(2;21;22)(p23;q22.1;q13) in desmoplastic tumor, 64:189
 t(3;3)(q21;q26) in RAEB-T, 59:138
 t(3;4)(q11;q11) in renal cancer, 64:30
 t(3;5)(p11;p12) in renal cancer, 64:30
 t(3;5)(p13;q22) in renal cancer, 64:30
 t(3;5)(p14;q22) in renal cancer, 64:30
 t(3;5)(p21;p15) in leiomyosarcoma, 62:43
 t(3;5)(p21;q35) in ANLL, 58:18
 t(3;5)(p24;q11) in M5 ANLL, 61:25
 t(3;5)(q21;q31) in ALL, 61:106
 t(3;5)(q21;q31) in gastric cancer, 58:79
 t(3;5)(q21;q31) in M6, 60:121
 t(3;5)(q21;q32) in M2 ANLL, 61:24
 t(3;5)(q26;q33) in M2 ANLL, 61:24
 t(3;6)(p11;q12) in melanoma cell line, 62:111
 t(3;6)(q13.3;q22) constitutional change in meningioma patient, 61:50
 t(3;6;14)(p21;p21;q24) in lung hamartoma, 60:219
 t(3;7)(p11;q36) in craniopharyngioma, 60:212
 t(3;7)(p13;q12) in Sézary syndrome, 58:102
 t(3;7)(p21;q35) in ANLL, 58:18
 t(3;7)(p25;q22) in ALL, 61:106
 t(3;7)(p26;p15) in ALL, 61:106
 t(3;8)(p14.2;q24.1) in familial RCC, 63:25
 t(3;8)(p21;q12) in pleomorphic adenomas, 58:86
 t(3;8)(p21;q24.1) in astrocytoma, 59:14
 t(3;8)(q12;q11) in colorectal cancer, 62:129
 t(3;8)(q12;q11.2) in lipoblastoma, 62:103
 t(3;8)(q12;p23) in Waldenström's macroglobulinemia, 58:89
 t(3;9)(q24;q11) in glioma, 58:113
 t(3;9;22)(p21;q34;q11) in CML, 61:152
 t(3;11)(p12;p12) in renal cancer, 64:30
 t(3;11)(p21;p15) in M7 ANLL, 61:25
 t(3;11)(q25;p11) in M4, 60:119
 t(3;12)(q25;q13) in ALL, 62:26
 t(3;13)(p13;q31) in SCC of head and neck, 59:73
 t(3;14)(p21;q32) in lymphoma, 59:68
 t(3;14)(q21;q32) SCC of head and neck, 59:73
 t(3;15)(p23;q15) in liposarcoma, 64:111
 t(3;15)(q13.3;q21) constitutional change in cervical cancer patient, 61:50
 t(3;17)(q26;q22) in accelerated phase of Ph + CML, 60:90
 t(4;5)(q13;q33) in astrocytoma, 59:14
 t(4;6)(p15;p12) in MDS, 59:161
 t(4;8)(q11;q24.2) SCC of head and neck, 59:73
 t(4;9)(q21;p22) in M2, 60:119
 t(4;11)(q21;q23) in ALL, 59:191; 61:106
 t(4;11)(q21;q23) in ALL (L2), 62:155
 t(4;11)(q21;q23) in congenital leukemias, 61:124
 t(4;11)(q34;q12) in lung cancer, 59:1, 3
 t(4;12)(p14;q23) in RAEB, 61:180
 t(4;12;19)(q35;q13;q13.1) in rhabdomyosarcoma, 60:135
 t(4;14)(q21;q32) in ANLL (M1), 59:48
 t(4;14)(q31;q32) in ANLL (M5), 59:48
 t(4;15)(p11;q15) in childhood ANLL, 58:155
 t(4;15)(q22;q15) in SCC of head and neck, 59:73
 t(4;16)(q13;p11) SCC of head and neck, 59:73
 t(4;16)(q13;q23) in lung cancer, 59:1, 3

- t(4;16)(q35;q22) in ANLL (M2), 59:48
 t(4;19)(q35.1;q13.1) in embryonal rhabdomyosarcoma, 61:214
 t(5;7)(q11;q36) in renal cancer, 64:30
 t(5;7)(q13;p22) in ANLL (M2), 59:48
 t(5;7;12)(q13;p11;p11) in MDS, 62:157
 t(5;8;12) in pleomorphic adenomas, 58:86
 t(5;9)(q12;q13) in renal cancer, 64:30
 t(5;10;14;17)(q11.2;q26;q24;q11.2) in ALL, 61:106
 t(5;11)(q35;q13) in renal cancer, 64:30
 t(5;11)(p15.2;q12) SCC of head and neck, 59:73
 t(5;12)(p13;p12) in ALL, 61:106
 t(5;12)(p15;q14) in pleomorphic adenomas, 58:86
 t(5;13)(q11.2;p11) in metastatic melanoma, 64:122
 t(5;13)(q31;q34) in RAEB-t, 63:97
 t(5;14)(p15;q21) in renal cancer, 64:30
 t(5;14)(q31;q32) in ALL, 61:106
 t(5;15)(q11;p11) in SCC of head and neck, 59:73
 t(5;15)(q11;q11) in renal cancer, 64:30
 t(5;17)(q22;q22) in lymphoma, 61:106
 t(5;17)(q35;q21) in MDS, 62:100
 t(5;18)(q35;p11.2) SCC of head and neck, 59:73
 t(5;22)(p14;q11) in lung cancer, 59:1, 3
 t(5;22)(q35;q11) in Askin tumor, 62:203
 t(6;7)(p21;p22) in uterine stromal sarcoma cell line, 60:60
 t(6;7)(q27;q11.2) in rhabdoid tumor, 59:14
 t(6;8)(p21;q24) in lymphoma, 61:33
 t(6;8)(q12;q13) in hepatocellular cases, 58:191
 t(6;8)(q22;q12) in Ph+ CML, 61:104
 t(6;9)(p21;q34) in ANLL (M6), 59:48
 t(6;9)(p22;q34) in AML (M1), 63:76
 t(6;11)(p12;p11.2) in cancer of Bartholin gland, 61:26
 t(6;12)(q23;q13) in phyllodes tumor, 60:74
 t(6;12)(q25;q13) in chondrosarcoma, 60:35
 t(6;14)(p21.1;q24) in T-cell lymphoma cell line, 59:199
 t(6;14)(q21;q32) in craniopharyngioma, 60:212
 t(6;15)(q25-26;q15) in ANLL (M4), 59:48
 t(6;17)(p23;q22) in myelofibrosis, 61:6
 t(6;18)(p22;q24) in colorectal cancer, 62:32
 t(6;21)(q13;q22) in M1 ANLL, 61:24
 t(6;21;18)(p21;q22;p11) in M5, 58:71
 t(7;7)(p22;q32) in giant cell tumor, 58:5
 t(7;7)(q13;q12) in Sézary syndrome, 58:102
 t(7;7)(q22;p21) in M2 ANLL, 61:24
 t(7;9)(p21;q12) in ependymoma, 58:116
 t(7;9)(q22;q34) in M2 ANLL, 61:24
 t(7;9;22) in CML, 58:143
 t(7;11)(q22;p13) in RAEB, 64:13
 t(7;12)(q22;p12) in M1 ANLL, 61:24
 t(7;12)(q34;p11) in M5 ANLL, 61:25
 t(7;13)(q11;q34) in ALL, 64:50
 t(7;15)(p12;q11) in lung cancer, 59:1, 3
 t(7;15)(q35;q15) in myelofibrosis, 61:6
 t(7;16)(p15;p13.3) in astrocytoma, 59:14
 t(7;17)(p21;p11) in cardiac myoma, 63:73
 t(7;17)(q22;q21) in ALL, 58:123
 t(7;22)(q31;q12) in leiomyoma, 59:219
 t(8;9)(q21;p21) in M2 ANLL, 61:24
 t(8;10)(q13;p13) in gastric cancer, 64:170
 t(8;11)(q12-13;q21) in rhabdomyosarcoma, 58:210
 t(8;12;14)(q24;p11;q21q32) in Burkitt lymphoma, 60:206
 t(8;13)(q24;q14) constitutional in lymphoma patient, 59:80
 t(8;14)(q24;q13) in T-ALL cell line, 64:86
 t(8;14)(q24;q31) in ALL (L3), 62:155
 t(8;14)(q24;q32) in Burkitt lymphoma, 60:206
 t(8;14)(q24;q32) in lymphoma, 61:34
 t(8;14)(q24;q32) in L3 ALL, 60:206; 61:218
 t(8;14)(q24;q32) in M2, 60:119
 t(8;15)(p21;q13) in leiomyosarcoma, 62:43
 t(8;15)(p23.1;q13.3) in hairy cell leukemia, 62:186
 t(8;15)(q12;q26) in pleomorphic adenomas, 58:86
 t(8;15;21)(q22;q21;q22) in ANLL (M2), 64:35
 t(8;16)(p11;p13) in M5 ANLL, 61:25
 t(8;16)(q11-12;q22) in M4, 58:204
 t(8;17)(q11;p11) in renal cancer, 64:30
 t(8;17)(q12;p11) in colorectal cancer, 62:192
 t(8;17)(q24;q23) in ependymoma, 58:116
 t(8;20)(q11;p11) SCC of head and neck, 59:73
 t(8;21) and t(15;17) in APL (M3), 58:177
 t(8;21)(q22;q22) in ANLL (M1, M2, M4), 62:156
 t(8;21)(q22;q22) in blast crisis of Ph+ CML, 58:96
 t(8;21)(q22;q22) in childhood ANLL, 58:155
 t(8;21)(q22;q22) in M2, 60:119
 t(8;21)(q22;q22) in M4Eo, 60:120; 61:24
 t(8;21)(q22;q22) in RAEB-t, 64:15
 t(8;22)(p12;q12) in M5 ANLL, 61:25
 t(8;22)(q22;q22) in RAEB, 58:76
 t(8;22)(p11;q13) in M5, 60:180
 t(9;10)(q22;q26) in lentigo maligna, 60:141
 t(9;11)(p22;q23) in blast phase of CML, 63:37
 t(9;11)(p22;q23) in childhood ANLL, 58:155
 t(9;11)(p22;q23) in M5, 60:120; 61:25
 t(9;12)(p24;q22) in thyroid cancer, 59:51
 t(9;12)(q12;p11) in chordoma, 61:95
 t(9;12)(q34;q15) in CML, 61:152
 t(9;14)(p22;q11) SCC of head and neck, 59:73
 t(9;15)(q11;p13) in renal cancer, 64:30
 t(9;19)(p13;q13.1) in lymphoma, 61:34
 t(9;22)(q34;q11) in ALL, 59:191; 63:89
 t(9;22)(q34;q11) in ALL (L1), 62:155
 t(9;22)(q34;q11) in ANLL (M2), 62:156
 t(9;22)(q22;q11) in chondroblastoma, 58:14
 t(9;22)(q22;q11) in CML, 61:126, 152, 198; 62:157
 t(9;22)(q34;q11) in myelofibrosis, 59:89
 t(9;22)(q34;q11) in M4, 58:29
 t(9;22)(q34;q11.2) in ALL, 61:106
 t(10;11)(p11;q13) in glioma, 58:113
 t(10;11)(p13;q14) in M5 in Klinefelter patient, 61:99
 t(10;11)(p15;p23) in M5 ANLL, 61:25
 t(10;11)(q22.3;p11.2) in embryonal rhabdomyosarcoma, 61:214
 t(10;11)(q24;q21) in M2 ANLL, 61:24
 t(10;11)(q26;p11.2) in lentigo maligna, 60:141
 t(10;11;19)(q22;q25;q13) in childhood ANLL, 58:156
 t(10;12)(p13;q15) in ALL, 59:191
 t(10;12)(q11.2;p11.1) in MFH, 59:30
 t(10;12)(q25;q15) in lipoma, 64:163
 t(10;13)(q11;p13) in hepatocellular cancer, 58:191
 t(10;13)(q22;q12) in lymphoma, 61:33
 t(10;13)(q22;q32) SCC of head and neck, 59:73
 t(10;16)(p11;q24) in C-cell thyroid hyperplasia, 59:51

- t(10;16)(q22;p11) in phyllodes tumor, 60:74
 t(10;17)(q24;q11.2) in CML, 61:152
 t(10;19)(q11.2;q24;p13.3) in metastatic melanoma, 64:122
 t(11;11)(p15;q13) in giant cell tumor, 58:5
 t(11;12)(p11;q13) in neuroectodermal, 59:14
 t(11;12)(p15;q13) in liposarcoma, 64:111
 t(11;12)(q13;q24) in ANLL (M4), 59:48
 t(11;14)(p13;q11) in ALL, 64:50
 t(11;14)(p13;q11) in ALL (L1), 62:155
 t(11;14)(q23;q24) in CMMoL, 61:162
 t(11;15)(q13;p13) in leiomyosarcoma, 62:43
 t(11;17)(q13;q11) in neuroblastoma cell line, 59:128
 t(11;17)(q13;q21) in ependymoma, 59:213
 t(11;17)(q13;q21) in liposarcoma, 64:111
 t(11;17)(q23;q23) in M5 ANLL, 61:25
 t(11;18)(p11;p11) in giant cell tumor, 58:5
 t(11;18)(p15;p11) in giant cell tumor, 58:5
 t(11;18)(q13;p11) in glioma, 58:111
 t(11;19)(q12 or 13.1;p12 or 13.1) in stromal sarcoma of breast, 63:47
 t(11;19)(q13;q13.4) in hamartoma, 58:141
 t(12;14)(p12;q32) in ANLL, 58:18
 t(12;14)(q11;p11) in leiomyosarcoma, 62:43
 t(12;14)(q14-15;q23-24) in leiomyomas, 62:40
 t(12;14)(q15;q22) in lipoleiomyoma, 62:200
 t(12;14)(q13;q32) in RAEB-t, 64:15
 t(12;16)(q13;q11) in liposarcoma, 64:111
 t(12;17)(p12;q11) in ALL (L1), 64:27
 t(12;18;17)(q15;q21.3;p12) in pleomorphic adenomas, 58:86
 t(12;19)(q13;p13.3) in metastatic melanoma, 64:122
 t(12;19)(q13;q13) in chondrosarcoma, 60:35
 t(12;22)(q13;q12-13) in malignant melanoma of soft parts, 60:176
 t(12;22)(q13;q13) in clear cell sarcoma, 64:101, 104, 107
 t(13;14)(q10;q10) in CMMoL, 64:15
 t(13;14)(q12.2;q32.3) in CMMoL, 60:190
 t(13;15)(q14;q24) SCC of head and neck, 59:73
 t(13;17)(q12;p11) in colorectal cancer, 62:192
 t(13;20)(q12;p13) in leiomyosarcoma, 62:43
 t(14;15)(q32;q11) in renal cancer, 64:30
 t(14;16)(q24;q22) in ALL, 59:191
 t(14;17)(q11;p11) in colorectal cancer, 62:192
 t(14;17)(q32;q31) in ANLL, 64:80
 t(14;17)(q32.3;q21.31) in embryonal rhabdomyosarcoma, 61:214
 t(14;18)(q32;q21) in lymphoma, 59:68; 61:33
 t(14;19)(q12;p12) in lung cancer cell line, 59:111
 t(15;17)(p11;q11) in M5 ANLL, 61:25
 t(15;17)(p12;p13) in ANLL (M2), 59:48
 t(15;17)(q14;p12) in RAS, 61:179
 t(15;17)(q22;q21) in ANLL (M3), 61:24; 62:156
 t(15;19)(q11;p11) in clear cell sarcoma, 64:104
 t(15;21)(p11;q11) in renal oncocytoma, 61:61
 t(15;21)(q21;q22) in AML, 61:139
 t(15;22)(p11;q11) in lymphoma, 59:68
 t(16;16)(p13;q22) in M4Eo, 60:120
 t(16;16)(q22;q22) in M4 ANLL, 61:24
 t(16;19)(q12;q13) in medullary thyroid adenoma, 60:99
 t(16;21)(p11;q22) in Ph+ CML, 60:210
 t(16;21)(p13;q12) in M5 ANLL, 61:25
 t(17;18)(p12;p11) in colorectal cancer, 62:192
 t(17;20)(q21;p12) in colorectal cancer, 64:183
 t(17;21)(p11;p11) in ANLL (M2), 59:48
 t(20;22)(p13;q11) and del(9)(q34) in myelofibrosis, 59:89
 t(20;22)(q13.3;q12) in lymphoma, 61:33
 t(X;1)(p11.2;q21) in renal cancer, 63:100
 t(X;9)(q13;p23) SCC of head and neck, 59:73
 t(X;9)(q27;q13) in Sézary syndrome, 58:102
 t(X;9;10;12)(p21;p12;p14;q13-14) in pleomorphic adenomas, 58:86
 t(X;11)(q12;p13) in melanoma cell line, 62:111
 t(X;14)(q11;q11) in colorectal cancer, 62:32
 t(X;22)(q21;q11) in colorectal cancer, 62:192
 t(Y;6;12)(q12;q23;q22) SCC of head and neck, 59:73
 t(Y;22)(q11.2;p12) in prostate cancer, 61:165
- Trisomy**
 in cases with t(1;7)(p11;p11) in ANLL, 60:117
 in childhood ANLL, 58:155
 in gastric cancer, 58:70
 in lymphoma, 58:56
 in MDS and ANLL, 62:27
 +2 in proliferative fascitis, 60:27
 +4 in ALL, 62:88
 +4 in ANLL, 60:195
 +4 in literature, 62:90
 +5 in Ph+ ANLL, 61:216
 +7 in gliomas, 58:109
 +7 in nonmalignant steatosis of liver, 63:22
 +7 in renal cancer, 64:30
 +7 in thyroid tumors, 62:144
 +8 and +11 in RAEB-T, 62:98
 +8 in clear cell sarcoma, 64:107
 +8 in CLL, 62:108
 +8 in MDS, 62:70
 8,11,15 in secondary ANLL, 58:18
 +12 in EBV transformed cell lines, 60:164
 +13 in APL, 62:206
 +14 in granular cell tumor, 60:202
 +14 in RAEB, 59:9
 +21 and 9q- in M2, 64:91
 +21 in MDS changing to acute leukemia, 64:56D
- Tumors**
 benign and malignant; stepwise process of carcinogenesis, 63:104
 cervix, 58:134
 chromosome 7 and premalignant progression in chemically induced tumors, 59:108
 clonal origin of multiple tumors in female genital tract, 63:130
 diminution of telomeres in tumors, 63:144
 epithelial tumors: methods, 63:104
 haploid clones in, 60:147
 liver, 58:191
 mechanism of extrachromosomal amplification, 63:109
 polymorphism of constitutional and tumor DNA by Alu-PCR, 63:109
 stomach, 58:79
 thyroid, 59:51
 Wilms, 59:104; 61:111

- Turcot syndrome
case report, 63:176
colonic polyposis in, 63:176
- Ultraviolet radiation
chromosome changes, 60:111
effects on fibroblasts of BCE patients, 61:74
xeroderma pigmentosum, 60:111
- Urothelial carcinoma; also see Bladder tumors
chromosomal loss seen with double staining of tissue sections, 63:108
- Uterus
cell line of stromal sarcoma, 60:60
cervical neoplasia, 60:214
chromosome changes in leiomyomas, 59:106, 217; 61:131; 62:40
chromosome changes in Mullerian tumor, 60:78
cytogenetics of stromal sarcoma, 60:60; 63:43
endometrial stromal sarcoma, 63:43; 132
FISH analysis of leiomyomas, 62:40
FISH studies in stromal sarcoma, 63:43
interphase analysis of leiomyomas, 62:40
leiomyomas of, 59:106; 217; 61:131; 62:40
Mullerian tumor (mixed, malignant), 60:78
stromal sarcoma, 60:60
t(7;17) in stromal sarcoma, 63:43
t(7;17)(p15-21;q12-21) in endometrial sarcoma, 63:132
- Uveal melanoma
chromosomes 3,6 and 8 in, 63:182
- Viruses
cervical cancer and papillomavirus, 59:173
EBV transformed cell lines and +12, 60:164
herpes simplex and chromosomal breakpoints, 59:135
integration and chromosomal fragility, 60:1
integration into fibroblasts, 60:1
papillomavirus and chromosomal breakpoints, 59:135
papillomavirus and effects on lymphocytes, 59:173
viruses and cervical carcinoma, 59:135
- Waldenström's macroglobulinemia
chromosome abnormalities, 61:147
chromosome changes, 58:89; 61:147
HSR in, 61:147
i(6p) in, 58:89
- Wilms tumor
chromosome and molecular studies, 59:104; 61:111
chromosomes 1p,16q and 17p in, 61:111
clonal evolution, 60:102
imprinting at 11p15, 63:163
mutation analysis, 63:170
of childhood, 61:111
telomeric fusion, 63:170
- X chromosome
abnormal X in M4, 62:130
FISH studies in M4, 62:130
in gastric cancer, 58:79
in germ cell tumors, 58:59
in testicular tumor, 58:59
in renal tumors, 59:104
inv(X) in leiomyosarcoma, 61:131
ring X in M4, 62:130
X-linked gene MICS, 60:20
X-linked polymorphism of HRPT gene in Chinese females, 64:192
-X in Waldenström's macroglobulinemia, 61:147
- X-linked proliferative disease (XLP)
Burkitt lymphoma in, 64:42
genetic events in lymphoma genesis, 64:42
- Xeroderma pigmentosum
lack of correlation with UV induced changes, 60:111
skin cancer, 60:111
variant and group E patients, 60:111
UV induced chromosome changes, 60:111
- Y chromosome
duplication in secondary ANLL, 58:18
in germ cell tumors, 59:54
in renal tumors, 59:104; 64:30
in testicular tumors, 59:54; 64:21
rearrangements in M2 ANLL, 61:101
-Y in gastric cancer, 61:39
-Y in gliomas, 58:109
-Y in hepatocellular carcinoma, 58:191
-Y in prostate cancer, 61:165
-Y in renal oncocytoomas, 61:61, 108
-Y in Waldenström's macroglobulinemia, 61:147
- YAC chromosomes
in myxoid liposarcoma, 62:166
spanning t(12;16) in LPS, 62:166